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ABSTRACT

CYTOTOXIC PROPERTIES OF NOVEL PLATINUM COMPOUNDS, BBR3610-DACH
AND TRANS-NBD IN TUMOR CELLS:
CELLULAR EFFECTS OF THE 1, 2-DACH AND NBD LIGANDS
By Vijay Menon, M.Sc.
A dissertation submitted in partial fulfillment of the requirements for the degree of Doctor of
Philosophy at Virginia Commonwealth University.
Virginia Commonwealth University, 2013
Advisor: Nicholas Farrell, Ph.D.
Professor, Department of Chemistry
Platinum-based chemotherapeutics are used for the treatment of a wide range of cancers and a
number of attempts have been made toward developing compounds with better cellular stability
and similar or enhanced cytotoxicity as compared to their predecessors.
The first part of the work reported here focuses on the cellular effects of the metabolically stable
dinuclear platinum compound, BBR3610-DACH. Comet assay showed this compound to form
interstrand crosslinks, a highly toxic DNA lesion in HCT116 cells, at equimolar concentrations
to its parental compound, BBR3610. Cell cycle studies showed that BBR3610-DACH causes
G1/S and G2/M cell cycle arrest with S phase depletion, which was p21 dependent and partially
p53 dependent in contrast to BBR3610 which showed initial S phase accumulation followed by a
classical G2/M arrest. BBR3610-DACH-induced G1/S and G2/M cell cycle arrest interestingly
was found to be independent of the DNA damage response mediated via the activation of ATM

xv

and ATR kinases. Also, the cell cycle arrest culminated in apoptosis, although apparently
through a non-canonical pathway.
The second project explores the cellular effects of trans-4-NBD which is a fluorescent derivative
of transplatin. Like cisplatin, trans-4-NBD induced interstrand crosslinks in HCT116 cells as
detected by the comet assay. Treatment with trans-4-NBD showed a G2/M arrest in HCT116
cells and a transient S phase accumulation in A2780 cells, with a marked increase in p53 and p21
protein levels. A robust apoptotic response is also seen via caspase activation and PARP
cleavage in both the cell lines.
Finally, the focus is shifted toward the nucleolar targeting platinum complex, TriplatinNC.
Confocal studies in TriplatinNC-treated HCT116 and A2780 cells showed disruption of rRNA
transcription as an early event followed by a robust G1 cell cycle arrest. Apoptotic induction was
observed with the onset of cellular morphological changes and apparent caspase activation which
was independent of the p53 status of the cells.
Overall, these studies explore novel platinum based compounds that show promising anti-cancer
activities by affecting various facets of cellular signaling.

CHAPTER 1

GENERAL INTRODUCTION

Cancer is one of the major contributors to world mortality. It is estimated that 1 in every 4 deaths
in the Unites States is due to cancer. According to recent Cancer Statistics1 a total of 1,660,290
new cancer cases and 580,350 cancer deaths have been predicted to occur in 2013. However,
cancer death rates have shown a 20% decline since 1991. This reduction could be attributed to
different forms of treatments like surgery, radiotherapy, and chemotherapy.

Chemotherapeutic intervention has its roots as early as 1940 with the use of nitrogen mustards
(alkylating agents) and antagonists against folic acid. Since then, the use of cancer drugs has
constantly evolved starting with Zubrod’s initiatives that included the taxanes (anti-microtubule
agents) and camptothecins and bleomycin (anti-tumor antibiotics) to the nitrosoureas (alkylating
agents) and anthracyclines (anti-tumor antibiotics) to the more widely used transition metal
complexes. These form some of the major classes of chemotherapeutics2 along with compounds
that do not fall under these categories like monoclonal antibodies and signaling inhibitors.
Although chemotherapy is a widely used treatment regimen along with radiation, most of the
cancer drugs have been shown to be carcinogenic and induce toxic side effects.

1

Cisplatin and analogs

Platinum-based compounds are one of the major classes of cancer chemotherapeutics. Cisplatin
(Fig 1-1), first discovered by Michael Peyrone in 1845, was later recognized serendipitously for
its chemotherapeutic ability in 1964 by Barnett Rosenberg3 who observed an incredible
elongation of E.coli cells4 when electricity was passed through platinum electrodes immersed in
the bacterial solution. Eventually, cisplatin was found to be effective against tumors induced in
mice and subsequently entered clinical trials in 19715. In spite of being an efficient anti-cancer
agent, use of cisplatin was accompanied with serious side effects like nephrotoxicity and
ototoxicity6, 7. Also, the development of intrinsic and acquired drug resistance hindered the
efficacy of cisplatin in many forms of cancer. These mainly included decreased drug uptake8,
increased drug efflux9, intracellular degradation by glutathione and metallothionein10-12, increased
DNA repair13-15, and alterations in different signaling pathways. In order to circumvent these
issues, carboplatin (Fig 1-1) was developed and introduced in the late 1980s16, 17. Although
carboplatin decreased most of the toxic side effects of cisplatin, the major side effect associated
with it was myelosuppression18. Also, it was not very effective in cisplatin-resistant tumors and
eventually its usage led to drug resistance as seen for cisplatin. In spite of these drawbacks,
carboplatin is widely used for the treatment of lung cancer in combination with gemcitabine19.
The third generation drug, oxaliplatin (Fig 1-1), which was approved for clinical use (Europe,
1996 and United States, 2000) after cisplatin and carboplatin, was widely used for the treatment
of colorectal cancers, owing to a different structure and mechanism of action compared to its
predecessors20. It was found to have an improved therapeutic index in colon cancers which could

2

be attributed to the rate of its uptake into cells. It was seen that the human organic cation
transporters (OCT1 and OCT2) increased the uptake of oxaliplatin21 but not cisplatin or
carboplatin. The anti-cancer activity of oxaliplatin was found to be markedly increased in
combination with other compounds especially 5-fluorouracil and folinic acid (FOLFOX).
However, as observed for cisplatin or carboplatin, the use of oxaliplatin led to side effects like
hematological toxicity and GI tract toxicity22. Also, drug resistance developed which was
primarily due to increased DNA repair and increased drug efflux.

3

Figure 1-1. Structures of Cisplatin (Left), Carboplatin (Center), and Oxaliplatin (Right)

4

Types of DNA adducts

The main pharmacological target of platinum drugs is DNA. The cytotoxicity of cisplatin,
carboplatin, and oxaliplatin is attributed to the formation of DNA adducts23,

24

wherein the

platinum moiety forms a bond with N7 of guanine or adenine. This leads to the formation of 1, 2GG intrastrand crosslinks that form the primary adducts of cisplatin25. The secondary adducts
constitute 1, 2-AG intrastrand crosslinks, 1, 3-GXG intrastrand crosslinks, and 1, 2-GG
interstrand crosslinks (Fig 1-2). While cisplatin and carboplatin form identical DNA adducts,
oxaliplatin adducts are more bulky owing to the presence of the 1, 2-diaminocyclohexane
moiety26-28 (Fig 1-1). These DNA adducts pose serious threats to different DNA transactions like
replication, transcription, and recombination. As a result, one of the major resistance
mechanisms elicited by cells in response to these drugs is increased DNA repair.

5

Figure 1-2. DNA adducts formed by cisplatin or carboplatin (Top) and oxaliplatin (Bottom)

6

Transplatin and Transplatinum Compounds

It is a well known fact that the trans isomer of cisplatin, trans-[PtCl2(NH3)2] or transplatin (Fig
1-3) is chemotherapeutically inactive29. This inactivity is mainly attributed to kinetic instability
leading to its degradation and the formation of DNA adducts that are stereochemically different
from cisplatin induced adduct. In spite of this inactive nature of transplatin, a surge in novel
platinum compounds with trans geometry was seen when Farrell et al. first reported a series of
transplatinum compounds (Fig 1-3) with increased activity over transplatin and in most cases,
equivalent to cisplatin. These were obtained by replacing the primary transplatin amines with Ndonor heterocycles, aliphatic amines, heterocyclic aliphatic amines, and iminoethers30, 31. It is
believed that the substitution with bulky ligands retards the chloride ligand substitution, leading
to increased kinetic stability. Also, the formation of DNA adducts, structurally different from
cisplatin renders these compounds active in most of the cisplatin-resistant tumors.

One possible reason for the increased activity observed especially in transplatinum complexes
containing heterocyclic derivatives is the intercalation or pi-stacking of these derivatives
between DNA bases leading to the formation of distinct DNA adducts32. Another modification
that has been carried out is to conjugate platinum compounds with aromatic intercalators like
anthraquinone and other cytotoxic moieties33. One such modification discussed in Chapter 4, was
the development of transplatinum complexes containing a fluorophore like NBD that also acts as
a DNA intercalator. These compounds, designated as Trans-NBD (Fig 1-3), exhibit a dual mode
of DNA interaction which is DNA crosslinking via the transplatin moiety and DNA intercalation

7

via the NBD fluorophore. Also, the presence of the fluorophore renders these compounds ideal
for imaging studies in order to better understand their exact cellular distribution and subsequent
cellular actions.

8

Figure 1-3. Structures of transplatin (Top), transplatinum compounds (Center),
and trans-NBD (Bottom)

9

Polynuclear platinum compounds

Polynuclear platinum complexes constitute a distinct class of antitumor agents, different in
structure and biological effects from their mononuclear counterparts represented by cisplatin and
its congeners34. These compounds, containing two or more platinum coordination units were an
important addition to the cancer armamentarium. [{trans-PtCl(NH3)2}2{l-trans-Pt(NH3)2
(H2N(CH2)6NH2)2}]4+ or BBR3464 (Fig 1-4), the first in this series of compounds, is a trinuclear,
bifunctional DNA binding agent with a 4+ charge and was the only non-cisplatin compound to
enter phase II of clinical trials for the treatment of ovarian and lung cancers35.

The bifunctional DNA binding is characterized by the formation of long range intrastrand or
interstrand crosslinks with more preference for the latter36, 37. Since BBR3464 is structurally
different than cisplatin or its congeners, the DNA adducts induced by BBR3464 are also
structurally distinct. Initial studies with BBR3464 revealed a non-covalent preassociation of the
central platinum with DNA. Some of the long range DNA adducts formed by BBR3464 are 1, 4
and 1, 6 interstrand crosslinks (Fig 1-5) that are not normally recognized by DNA repair
proteins. As a result, these lesions prove to be major obstacles during DNA replication or
transcription and at the same time escape DNA repair. Although BBR3464 exhibited enhanced
antitumor effects against a wide range of cancer cell lines, it exhibited increased cellular toxicity
which led to its failure in clinical trials. This was attributed to its increased biotransformation in
the serum that contributed toward its instability38, 39.
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During the examination of the structure activity relationship of polynuclear platinum compounds,
one of the main questions was whether the central platinum in BBR3464 could be replaced by
other H-bonding groups and whether such a modification would retain its cytotoxicity. This led
to the synthesis of linear polyamine-linked dinuclear compounds that displayed a similar mode
of DNA binding and biological activity as BBR346440. The inclusion of polyamine linkers within
the alkanediamine chain of BBR3464 not only provided the required electrostatic interaction and
H-bonding but also provided a means for increased uptake owing to the polycationic nature of
the spermine or spermidine linkers. The first in this series of drugs, BBR3610 (Fig 1-4)
containing a spermine linker, was found to be cytotoxic in the nanomolar range in gliomas41.
However, BBR3610 was also found to be susceptible to serum breakdown which may have
contributed to its narrow therapeutic index42. As a result, many modifications of BBR3610 were
carried out to reduce its breakdown in serum and at the same time retain a considerable antitumor activity. Some of the modifications involved replacing the chloride ligands with
carboxylate groups like butyrate and capronate43 (Fig 1-4). The most recent modification was
BBR3610-DACH, discussed in detail in Chapter 2, wherein the primary amines at either ends of
BBR3610 is replaced with the more stable 1, 2- diaminocyclohexane ligand which provided
enhanced stability against glutathione degradation and showed remarkable cellular effects as
compared to the parental BBR361044.

The platinum drugs described so far bind to DNA covalently forming the specific adducts,
although the polynuclear compounds had a non-covalent pre-association due to the presence of
the central platinum or the polyamine linkers. An interesting modification carried out in
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BBR3464 was the replacement of the chloride ligands by inert or dangling amines,
H2N(CH2)6NH3. This resulted in a non-covalent trinuclear platinum compound, TriplatinNC45
(Fig 1-4). It showed a unique mode of DNA binding called the phosphate clamp which was
characterized by two different DNA interactions namely “backbone tracking” which involved the
association of the molecule with the phosphate backbone and “groove spanning” which involved
interaction with both DNA strands by passing over the minor groove46. This structure is similar
to the “arginine fork” seen in protein-DNA interactions. In addition to increased uptake and
resistance to metabolic degradation47, this drug exhibited unique cellular effects, which is
described in detail in Chapter 4.
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Figure 1-4. Structures of polynuclear platinum compounds
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Figure 1-5. DNA adducts formed by BBR3464.
Picture from Polynuclear Platinum Drugs, Nicholas Farrell
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The formation of toxic DNA lesions by platinum drugs and other DNA targeting anti-cancer
drugs is one of the key mechanisms responsible for their efficacy in cancer cells. Also, DNA is
constantly under stress due to various endogenous processes like nucleotide misincorporation
during replication, byproducts of various cellular processes, etc. In order to maintain the genome
integrity and ensure normal development, organisms have evolved various DNA damage
responses that mainly involve activation of cell cycle checkpoints to arrest cell cycle progression,
various DNA repair pathways depending on the nature of DNA damage, and apoptotic pathways
when the DNA damage is severe.
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Cell Cycle Checkpoints and cell cycle arrest

Cell cycle arrest is primarily mediated via the activation of cell cycle checkpoints during various
phases of the cell cycle (Fig 1.6). The key players involved in the activation of cell cycle
checkpoints are the serine/threonine protein kinases, ATM (Ataxia Telangiectasia mutated) and
ATR (Ataxia Telangiectasia and Rad3 related). Both these proteins have a catalytic C terminal
motif containing a phosphatidylinositol 3-kinase domain48. Although these proteins
phosphorylate a myriad of cellular proteins, they function in response to specific DNA lesions or
damage. ATM primarily recognizes DNA double strand breaks while ATR recognizes
replication fork stalling due to UV and other agents that form bulky DNA adducts48. During the
G1 cell cycle checkpoint, one of the key steps is the stabilization and activation of the tumor
suppressor protein, p5349-51. Under normal circumstance, p53 levels are regulated by its
interaction with MDM252 which targets it for nuclear export and subsequent degradation in the
cytoplasm. Following DNA damage by UV or other agents, ATM activates Chk2 which in turn
phosphorylates p53 at serine 2048. Also, ATM can directly phosphorylate MDM253, still allowing
its interaction with p53 but no nuclear export. ATR, on the other hand, activates Chk1 which can
also phosphorylate p53 at serine 2048. In addition to these events, p53 is also phosphorylated at
serine 15 which is important for its transactivation activity. It then activates different
downstream genes, one of them being p21 which is a cyclinE/Cdk2 inhibitor, eventually leading
to G1 arrest. The S phase checkpoint is mainly activated in response to stalled replication forks
due to obstructions in DNA replication54. An important consequence is degradation of the
Cdc25A phosphatase via phosphorylation by Chk2 which is activated by ATM at S12355-57. The
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absence of Cdc25A prevents the inhibitory phosphorylations from being removed. The
Cdk2/cyclinE and Cdk2/cyclin A complexes become inactive and as a result DNA synthesis is
stalled. Since most of the platinum drugs form DNA crosslinks, it is expected that DNA
replication would stall leading to ATR activation and subsequent Chk1 activation. This concept
is further explored in Chapter 2.

Finally, the G2 phase checkpoint is also activated during DNA damage in cells before S phase
completion. ATR is eventually activated leading to Chk1 phosphorylation at S34558. Chk1 then
phosphorylates Cdc25C, creating a binding site for the 14-3-3 protein, either making Cdc25C
catalytically inactive or sequestering it in the cytoplasm59. This ultimately inhibits the mitotic
cyclin B.Cdc2 kinase and prevents the cells from entering mitosis. In cells that have incurred
DNA damage during the G2 phase, ATM is primarily activated leading to Chk2 phosphorylation
at Thr6860. Chk2 then phosphorylates Cdc25C at S21661, ultimately bolstering the cyclinB.Cdc2
inhibition imposed by the ATR-Chk1 pathway. Most of the anti-cancer agents that cause DNA
damage activate either of the above discussed checkpoints which are further explored in Chapter
2.
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Figure 1-6. Cell Cycle Checkpoints
(Adapted from multiple sources)
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DNA Repair Pathways

DNA repair pathways provide an ideal platform for tumor cells to survive DNA damage induced
by chemotherapeutic agents. Depending upon the nature of the damage, organisms have evolved
various mechanisms of DNA repair. As mentioned previously, one of the DNA damage
responses is triggered following UV radiation that causes two types of lesions namely
cyclobutane pyrimidine dimers and 6-4 photoproducts62. These are potentially deleterious lesions
that cause DNA bends and kinks, inhibiting DNA replication and transcription. These lesions are
repaired by the nucleotide excision repair (NER) which involves over 30 proteins (XPChHR23B, TFIIH that includes XPD and XPB helicases, XPA, XPG, and XPF-ERCC1), defects
in which are responsible for the human disorder, Xeroderma Pigmentosum63. Bacteria and some
other organisms repair UV induced damage by another mechanism called photoreactivation also
called light repair64 since it occurs only in the presence of light. It involves an enzyme,
photolyase that binds pyrimidine dimers and a second molecule called chromophore that
converts light energy into chemical energy, allowing the damaged DNA to revert to the normal
form. In addition to NER, another predominant form of DNA repair, which also plays a pivotal
role in the repair of mitochondrial DNA, is the base excision repair (BER) that repairs DNA
damage induced by reactive oxygen species and free radicals65, 66. Mismatch repair is a post
replication error correcting pathway that recognizes incorrectly incorporated nucleotides during
replication. After the mismatch is recognized, the newly replicated strand including the
mismatched base is excised and replaced with DNA repair synthesis and religation67-69.
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The most toxic DNA lesions encountered in the cells are the double strand break and the
interstrand crosslink since they involve both strands of DNA. DNA double strand breaks (DSBs)
are mainly resolved by two mechanisms, homologous recombination repair (HRR) and nonhomologous end joining (NHEJ)70, 71. The latter that occurs during all phases of the cell cycle is
carried out principally by a small number of core proteins such as the Ku heterodimer, DNAPKcs, Artemis, DNA Ligase IV, XLF, and XRCC472. In comparison, the HRR pathway requires
a pair of homologous sequences like sister chromatids or homologous chromosomes to replace
the nucleotides during repair. It involves a larger number of proteins including RAD51, RAD52,
RAD54, RAD55, RAD57, BRCA1, BRCA2, XRCC2, XRCC3, and MRN complex. It is an
error-free DNA repair mechanism and is most prevalent during the S/G2 phases of the cell
cycle73.

Interstrand crosslink repair (Fig 1-7) is a highly complex DNA repair pathway responsible for
resolving interstrand crosslinks (ICLs). As a result, it is one of the major factors responsible for
platinum drug resistance. Early work in E.coli has shown that interstrand crosslinks are repaired
through combined action of the nucleotide excision repair pathway (NER) and the homologous
recombination (HR) pathway74. The mechanism of interstrand crosslink (ICL) repair in
mammalian cells is much more complicated and most of the details are still unclear. Active
mainly in replicative cells, it involves the sequential activation of an error-free homologous
recombination process and an error-prone translesion bypass synthesis, along with a complex
interplay of proteins involved in NER75, 76. Briefly, when a replication fork collides with a
crosslink, a double strand break is created via the activity of different endonucleases77. The same
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strand is then cleaved on the other side of the lesion78, followed by unhooking of the crosslinking
and finally culminating in translesion synthesis through the agency of specialized polymerases79.
The bypassed crosslink is later removed by the nucleotide excision repair machinery and the gap
formed allows homologous recombination of the repaired chromatid with the sister80.

The proteins associated with the pathophysiology of Fanconi Anemia have a crucial role in ICL
repair. It is believed that these FA proteins assist in stabilizing replication forks and also assist
the replication machinery in the removal of ICLs81-83. The importance of the involvement of the
FA proteins reached a new dimension with the identification and characterization of a nuclease,
Fanconi Anemia associated nuclease 1 (FAN1), associated with platinum drug resistance84-87.
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*Figure 1-7. Interstrand crosslink repair. (1) DNA with interstrand crosslink.
(2) Stalling of replication fork 10-30 nucleotides away from the ICL. (3) A second
replication fork stops near the ICL on the opposite side. (4) One of the replication
forks continue forward and halt at the ICL. (5) Incision on one side of the ICL by
endonuclease (Mus81-Eme1). (6) Second incision on the other side by second
endonuclease (ERCC1-XPF). (7) Translesion bypass by polymerase (Rev1). (8)
Nucleotide inserted is extended by DNA polymerase ζ. (9) The flipped out crosslink is
removed by the NER machinery. (10) End resection of parental strand forms a 3´
overhang. (11) Strand invasion by homologous recombination forming d-loop. (12)
Strand switching. (13) The d-loop resolved via the FA pathway. (14) Repaired DNA
*Figure adapted and recreated from:
How the Fanconi Anemia Pathway Guards the Genome
Moldovan and D’Andrea
Annual Review of Genetics, Vol. 43: 223-249
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Apoptosis

Cells that are arrested in different phases of the cell cycle eventually undergo programmed cell
death or apoptosis. During an apoptotic response, a group of intracellular proteases called
caspases get activated and eventually cause the disruption of cellular components into apoptotic
bodies. These proteases are present in the cells as inactive zymogens that subsequently undergo
proteolytic activation88, 89. The two main pathways of apoptosis include: (1) the extrinsic pathway
that occurs via the binding of death ligands to their respective death receptors90, and (2) the
intrinsic pathway activated following DNA damage. Death receptors activate caspase-8 which in
turn either activates caspase-3 directly or cleaves Bid to give truncated Bid which then
translocates to the mitochondria91. Bid cleavage is also triggered via the intrinsic pathway which
is primarily activated following DNA damage. During this phase, mitochondrial disruption
occurs releasing cytochrome C into the cytoplasm which then complexes with APAF-1 forming
the apoptosome92. This complex then activates caspase-9 which then activates caspase-3. Both
pathways converge on activated caspase-3 which then cleaves downstream cellular substrates
like PARP which is also a DNA repair protein93. The induction of apoptosis following treatment
with platinum compounds will be discussed further in chapters 2, 3, and 4.

23

REFERENCES:

1. Siegel R, Naishadham D, Jemal A. CA: A Cancer Journal for Clinicians 2013; 63:11-30.
2. Davis W, Larionov LF. Progress in chemotherapy of cancer. Bull World Health Organ 1964;
30:327-41.
3. Rosenberg B, VanCamp L, Trosko JE, Mansour VH. Platinum compounds: A new class of
potent antitumour agents. Nature 1969; 222:385-6.
4. Rosenberg B, Vancamp L, Krigas T. Inhibition of cell division in Escherichia coli by
electrolysis products from a platinum electrode. Nature 1965; 205:698-9.
5. The discovery and development of cisplatin. J Chem Educ : 728.
6. Rybak LP, Whitworth CA, Mukherjea D, Ramkumar V. Mechanisms of cisplatin-induced
ototoxicity and prevention. Hear Res 2007; 226:157-67.
7. Arany I, Safirstein RL. Cisplatin nephrotoxicity. Semin Nephrol 2003; 23:460-4.
8. Loh SY, Mistry P, Kelland LR, Abel G, Harrap KR. Reduced drug accumulation as a major
mechanism of acquired resistance to cisplatin in a human ovarian carcinoma cell line:
Circumvention studies using novel platinum (II) and (IV) ammine/amine complexes. Br J Cancer
1992; 66:1109-15.
9. Zisowsky J, Koegel S, Leyers S, Devarakonda K, Kassack MU, Osmak M, et al. Relevance of
drug uptake and efflux for cisplatin sensitivity of tumor cells. Biochem Pharmacol 2007; 73:298307.
10. Wang And X, Guo Z. The role of sulfur in platinum anticancer chemotherapy. Anticancer
Agents Med Chem 2007; 7:19-34.
11. Andrews PA, Murphy MP, Howell SB. Metallothionein-mediated cisplatin resistance in
human ovarian carcinoma cells. Cancer Chemother Pharmacol 1987; 19:149-54.
12. Komiya S, Gebhardt MC, Mangham DC, Inoue A. Role of glutathione in cisplatin resistance
in osteosarcoma cell lines. J Orthop Res 1998; 16:15-22.
13. Kartalou M, Essigmann JM. Mechanisms of resistance to cisplatin. Mutat Res 2001; 478:2343.

24

14. Masuda H, Ozols RF, Lai GM, Fojo A, Rothenberg M, Hamilton TC. Increased DNA repair
as a mechanism of acquired resistance to cis-diamminedichloroplatinum (II) in human ovarian
cancer cell lines. Cancer Res 1988; 48:5713-6.
15. Chu G, Chang E. Cisplatin-resistant cells express increased levels of a factor that recognizes
damaged DNA. Proc Natl Acad Sci U S A 1990; 87:3324-7.
16. Smith IE, Harland SJ, Robinson BA, Evans BD, Goodhart LC, Calvert AH, et al.
Carboplatin: A very active new cisplatin analog in the treatment of small cell lung cancer.
Cancer Treat Rep 1985; 69:43-6.
17. Tamura T, Saijo N, Shinkai T, Eguchi K, Sasaki Y, Sakurai M, et al. Phase II study of
carboplatin in small cell lung cancer. Jpn J Clin Oncol 1988; 18:27-32.
18. Ozols RF, Ostchega Y, Curt G, Young RC. High-dose carboplatin in refractory ovarian
cancer patients. J Clin Oncol 1987; 5:197-201.
19. Zatloukal P, Petruzelka L. Gemcitabine/carboplatin in advanced non-small cell lung cancer.
Lung Cancer 2002; 38 Suppl 2:S33-6.
20. Raymond E, Faivre S, Chaney S, Woynarowski J, Cvitkovic E. Cellular and molecular
pharmacology of oxaliplatin. Mol Cancer Ther 2002; 1:227-35.
21. Zhang S, Lovejoy KS, Shima JE, Lagpacan LL, Shu Y, Lapuk A, et al. Organic cation
transporters are determinants of oxaliplatin cytotoxicity. Cancer Res 2006; 66:8847-57.
22. Cassidy J, Misset JL. Oxaliplatin-related side effects: Characteristics and management.
Semin Oncol 2002; 29:11-20.
23. Saris CP, van de Vaart PJ, Rietbroek RC, Blommaert FA. In vitro formation of DNA adducts
by cisplatin, lobaplatin and oxaliplatin in calf thymus DNA in solution and in cultured human
cells. Carcinogenesis 1996; 17:2763-9.
24. Malinge JM, Giraud-Panis MJ, Leng M. Interstrand cross-links of cisplatin induce striking
distortions in DNA. J Inorg Biochem 1999; 77:23-9.
25. Dijt FJ, Fichtinger-Schepman AM, Berends F, Reedijk J. Formation and repair of cisplatininduced adducts to DNA in cultured normal and repair-deficient human fibroblasts. Cancer Res
1988; 48:6058-62.
26. Chaney S. The chemistry and biology of platinum complexes with the 1,2diaminocyclohexane carrier ligand (review). Int J Oncol 1995; 6:1291-305.

25

27. Scheeff ED, Briggs JM, Howell SB. Molecular modeling of the intrastrand guanine-guanine
DNA adducts produced by cisplatin and oxaliplatin. Mol Pharmacol 1999; 56:633-43.
28. Woynarowski JM, Chapman WG, Napier C, Herzig MC, Juniewicz P. Sequence- and regionspecificity of oxaliplatin adducts in naked and cellular DNA. Mol Pharmacol 1998; 54:770-7.
29. Brabec V, Neplechova K, Kasparkova J, Farrell N. Steric control of DNA interstrand crosslink sites of trans platinum complexes: Specificity can be dictated by planar nonleaving groups. J
Biol Inorg Chem 2000; 5:364-8.
30. Coluccia M, Natile G. Trans-platinum complexes in cancer therapy. Anticancer Agents Med
Chem 2007; 7:111-23.
31. Radulovic S, Tesic Z, Manic S. Trans-platinum complexes as anticancer drugs: Recent
developments and future prospects. Curr Med Chem 2002; 9:1611-8.
32. Aris SM, Farrell NP. Towards antitumor active trans-platinum compounds. Eur J Inorg Chem
2009; 2009:1293.
33. Alderden RA, Mellor HR, Modok S, Hambley TW, Callaghan R. Cytotoxic efficacy of an
anthraquinone linked platinum anticancer drug. Biochem Pharmacol 2006; 71:1136-45.
34. Farrell N. Polynuclear platinum drugs. Met Ions Biol Syst 2004; 42:251-96.
35. Manzotti C, Pratesi G, Menta E, Di Domenico R, Cavalletti E, Fiebig HH, et al. BBR3464: A
novel triplatinum complex, exhibiting a preclinical profile of antitumor efficacy different from
cisplatin. Clin Cancer Res 2000; 6:2626-34.
36. Zehnulova J, Kasparkova J, Farrell N, Brabec V. Conformation, recognition by high mobility
group domain proteins, and nucleotide excision repair of DNA intrastrand cross-links of novel
antitumor trinuclear platinum complex BBR3464. J Biol Chem 2001; 276:22191-9.
37. Kasparkova J, Zehnulova J, Farrell N, Brabec V. DNA interstrand cross-links of the novel
antitumor trinuclear platinum complex BBR3464. Conformation, recognition by high mobility
group domain proteins, and nucleotide excision repair. J Biol Chem 2002; 277:48076-86.
38. Oehlsen ME, Qu Y, Farrell N. Reaction of polynuclear platinum antitumor compounds with
reduced glutathione studied by multinuclear (1H, 1H-15N gradient heteronuclear single-quantum
coherence, and 195Pt) NMR spectroscopy. Inorg Chem 2003; 42:5498-506.

26

39. Vacchina V, Torti L, Allievi C, Lobinski R. Sensitive species-specific monitoring of a new
triplatinum anti-cancer drug and its potential related compounds in spiked human plasma by
cation-exchange HPLC-ICP-MS. J Anal At Spectrom: 884.
40. McGregor TD, Hegmans A, Kasparkova J, Neplechova K, Novakova O, Penazova H, et al. A
comparison of DNA binding profiles of dinuclear platinum compounds with polyamine linkers
and the trinuclear platinum phase II clinical agent BBR3464. J Biol Inorg Chem 2002; 7:397404.
41. Billecke C, Finniss S, Tahash L, Miller C, Mikkelsen T, Farrell NP, et al. Polynuclear
platinum anticancer drugs are more potent than cisplatin and induce cell cycle arrest in glioma.
Neuro Oncol 2006; 8:215-26.
42. Summa N, Maigut J, Puchta R, van Eldik R. Possible biotransformation reactions of
polynuclear Pt (II) complexes. Inorg Chem 2007; 46:2094-104.
43. Gatti L, Perego P, Leone R, Apostoli P, Carenini N, Corna E, et al. Novel bis-platinum
complexes endowed with an improved pharmacological profile. Mol Pharm 2010; 7:207-16.
44. Zerzankova L, Suchankova T, Vrana O, Farrell NP, Brabec V, Kasparkova J. Conformation
and recognition of DNA modified by a new antitumor dinuclear Pt (II) complex resistant to
decomposition by sulfur nucleophiles. Biochem Pharmacol 2010; 79:112-21.
45. Komeda S, Moulaei T, Woods KK, Chikuma M, Farrell NP, Williams LD. A third mode of
DNA binding: Phosphate clamps by a polynuclear platinum complex. J Am Chem Soc 2006;
128:16092-103.
46. Komeda S, Moulaei T, Chikuma M, Odani A, Kipping R, Farrell NP, et al. The phosphate
clamp: A small and independent motif for nucleic acid backbone recognition. Nucleic Acids Res
2011; 39:325-36.
47. Benedetti BT, Peterson EJ, Kabolizadeh P, Martinez A, Kipping R, Farrell NP. Effects of
noncovalent platinum drug-protein interactions on drug efficacy: Use of fluorescent conjugates
as probes for drug metabolism. Mol Pharm 2011; 8:940-8.
48. Abraham RT. Cell cycle checkpoint signaling through the ATM and ATR kinases. Genes
Dev 2001; 15:2177-96.
49. Amundson SA, Myers TG, Fornace AJ,Jr. Roles for p53 in growth arrest and apoptosis:
Putting on the brakes after genotoxic stress. Oncogene 1998; 17:3287-99.
50. Agarwal ML, Agarwal A, Taylor WR, Stark GR. p53 controls both the G2/M and the G1 cell
cycle checkpoints and mediates reversible growth arrest in human fibroblasts. Proc Natl Acad
Sci U S A 1995; 92:8493-7.
27

51. Canman CE, Wolff AC, Chen CY, Fornace AJ,Jr, Kastan MB. The p53-dependent G1 cell
cycle checkpoint pathway and ataxia-telangiectasia. Cancer Res 1994; 54:5054-8.
52. Moll UM, Petrenko O. The MDM2-p53 interaction. Mol Cancer Res 2003; 1:1001-8.
53. Khosravi R, Maya R, Gottlieb T, Oren M, Shiloh Y, Shkedy D. Rapid ATM-dependent
phosphorylation of MDM2 precedes p53 accumulation in response to DNA damage. Proc Natl
Acad Sci U S A 1999; 96:14973-7.
54. Segurado M, Tercero JA. The S-phase checkpoint: Targeting the replication fork. Biol Cell
2009; 101:617-27.
55. Donzelli M, Draetta GF. Regulating mammalian checkpoints through Cdc25 inactivation.
EMBO Rep 2003; 4:671-7.
56. Bartek J, Lukas J. Chk1 and Chk2 kinases in checkpoint control and cancer. Cancer Cell
2003; 3:421-9.
57. Falck J, Mailand N, Syljuasen RG, Bartek J, Lukas J. The ATM-Chk2-Cdc25A checkpoint
pathway guards against radioresistant DNA synthesis. Nature 2001; 410:842-7.
58. Zhao H, Piwnica-Worms H. ATR-mediated checkpoint pathways regulate phosphorylation
and activation of human Chk1. Mol Cell Biol 2001; 21:4129-39.
59. Dalal SN, Schweitzer CM, Gan J, DeCaprio JA. Cytoplasmic localization of human Cdc25C
during interphase requires an intact 14-3-3 binding site. Mol Cell Biol 1999; 19:4465-79.
60. Matsuoka S, Rotman G, Ogawa A, Shiloh Y, Tamai K, Elledge SJ. Ataxia telangiectasiamutated phosphorylates Chk2 in vivo and in vitro. Proc Natl Acad Sci U S A 2000; 97:10389-94.
61. Wei F, Xie Y, Tao L, Tang D. Both ERK1 and ERK2 kinases promote G2/M arrest in
etoposide-treated MCF7 cells by facilitating ATM activation. Cell Signal 2010; 22:1783-9.
62. Cadet J, Sage E, Douki T. Ultraviolet radiation-mediated damage to cellular DNA. Mutat Res
2005; 571:3-17.
63. de Laat WL, Jaspers NGJ, Hoeijmakers JHJ. Molecular mechanism of nucleotide excision
repair. Genes & Development 1999; 13:768-85.
64. Goosen N, Moolenaar GF. Repair of UV damage in bacteria. DNA Repair (Amst) 2008;
7:353-79.
65. David SS, O'Shea VL, Kundu S. Base-excision repair of oxidative DNA damage. Nature
2007; 447:941-50.
28

66. LeDoux SP, Wilson GL. Base excision repair of mitochondrial DNA damage in mammalian
cells. Prog Nucleic Acid Res Mol Biol 2001; 68:273-84.
67. Modrich P, Lahue R. Mismatch repair in replication fidelity, genetic recombination, and
cancer biology. Annu Rev Biochem 1996; 65:101-33.
68. Lujan SA, Williams JS, Pursell ZF, Abdulovic-Cui AA, Clark AB, Nick McElhinny SA, et
al. Mismatch repair balances leading and lagging strand DNA replication fidelity. PLoS Genet
2012; 8:e1003016.
69. Hombauer H, Campbell CS, Smith CE, Desai A, Kolodner RD. Visualization of eukaryotic
DNA mismatch repair reveals distinct recognition and repair intermediates. Cell 2011; 147:104053.
70. San Filippo J, Sung P, Klein H. Mechanism of eukaryotic homologous recombination. Annu
Rev Biochem 2008; 77:229-57.
71. Valerie K, Povirk LF. Regulation and mechanisms of mammalian double-strand break repair.
Oncogene 2003; 22:5792-812.
72. Lieber MR. The mechanism of double-strand DNA break repair by the non-homologous
DNA end-joining pathway. Annu Rev Biochem 2010; 79:181-211.
73. Heyer WD. Biochemistry of eukaryotic homologous recombination. Top Curr Genet 2007;
17:95-133.
74. Cole RS. Repair of DNA containing interstrand crosslinks in Escherichia coli: Sequential
excision and recombination. Proc Natl Acad Sci U S A 1973; 70:1064-8.
75. Raschle M, Knipscheer P, Enoiu M, Angelov T, Sun J, Griffith JD, et al. Mechanism of
replication-coupled DNA interstrand crosslink repair. Cell 2008; 134:969-80.
76. McHugh PJ, Spanswick VJ, Hartley JA. Repair of DNA interstrand crosslinks: Molecular
mechanisms and clinical relevance. Lancet Oncol 2001; 2:483-90.
77. Hanada K, Budzowska M, Modesti M, Maas A, Wyman C, Essers J, et al. The structurespecific endonuclease Mus81-Eme1 promotes conversion of interstrand DNA crosslinks into
double-strands breaks. EMBO J 2006; 25:4921-32.
78. Niedernhofer LJ, Odijk H, Budzowska M, van Drunen E, Maas A, Theil AF, et al. The
structure-specific endonuclease ERCC1-XPF is required to resolve DNA interstrand cross-linkinduced double-strand breaks. Mol Cell Biol 2004; 24:5776-87.

29

79. Ho TV, Guainazzi A, Derkunt SB, Enoiu M, Scharer OD. Structure-dependent bypass of
DNA interstrand crosslinks by translesion synthesis polymerases. Nucleic Acids Res 2011;
39:7455-64.
80. Hinz JM. Role of homologous recombination in DNA interstrand crosslink repair. Environ
Mol Mutagen 2010; 51:582-603.
81. Knipscheer P, Raschle M, Smogorzewska A, Enoiu M, Ho TV, Scharer OD, et al. The
fanconi anemia pathway promotes replication-dependent DNA interstrand cross-link repair.
Science 2009; 326:1698-701.
82. Moldovan GL, D'Andrea AD. How the fanconi anemia pathway guards the genome. Annu
Rev Genet 2009; 43:223-49.
83. Jones MJ, Huang TT. The fanconi anemia pathway in replication stress and DNA crosslink
repair. Cell Mol Life Sci 2012.
84. Yoshikiyo K, Kratz K, Hirota K, Nishihara K, Takata M, Kurumizaka H, et al.
KIAA1018/FAN1 nuclease protects cells against genomic instability induced by interstrand
cross-linking agents. Proc Natl Acad Sci U S A 2010; 107:21553-7.
85. Smogorzewska A, Desetty R, Saito TT, Schlabach M, Lach FP, Sowa ME, et al. A genetic
screen identifies FAN1, a fanconi anemia-associated nuclease necessary for DNA interstrand
crosslink repair. Mol Cell 2010; 39:36-47.
86. Kratz K, Schopf B, Kaden S, Sendoel A, Eberhard R, Lademann C, et al. Deficiency of
FANCD2-associated nuclease KIAA1018/FAN1 sensitizes cells to interstrand crosslinking
agents. Cell 2010; 142:77-88.
87. MacKay C, Declais AC, Lundin C, Agostinho A, Deans AJ, MacArtney TJ, et al.
Identification of KIAA1018/FAN1, a DNA repair nuclease recruited to DNA damage by
monoubiquitinated FANCD2. Cell 2010; 142:65-76.
88. Boatright KM, Salvesen GS. Mechanisms of caspase activation. Curr Opin Cell Biol 2003;
15:725-31.
89. Budihardjo I, Oliver H, Lutter M, Luo X, Wang X. Biochemical pathways of caspase
activation during apoptosis. Annu Rev Cell Dev Biol 1999; 15:269-90.
90. Elmore S. Apoptosis: A review of programmed cell death. Toxicol Pathol 2007; 35:495-516.
91. Kruidering M, Evan GI. Caspase-8 in apoptosis: The beginning of "the end"? IUBMB Life
2000; 50:85-90.

30

92. Wang X. The expanding role of mitochondria in apoptosis. Genes Dev 2001; 15:2922-33.
93. Boulares AH, Yakovlev AG, Ivanova V, Stoica BA, Wang G, Iyer S, et al. Role of
poly(ADP-ribose) polymerase (PARP) cleavage in apoptosis. caspase 3-resistant PARP mutant
increases rates of apoptosis in transfected cells. J Biol Chem 1999; 274:22932-40.

31

CHAPTER 2

The dinuclear platinum agent, BBR3610-DACH, exhibits a significant anti- proliferative
effect in human colorectal HCT116 cells via modulation of
G1/S and G2/M cell cycle arrest and apoptosis induction:
Cellular effects of the 1, 2-DACH carrier ligand

ABSTRACT:

BBR3610-DACH, a long-chain, bifunctional dinuclear Pt (II) complex with a similar DNA
binding mode to the phase II clinical drug, BBR3464 and its potent analogue, BBR3610, was
shown previously to be resistant to metabolic decomposition by sulfur nucleophiles. Comet
analysis indicated that BBR3610-DACH formed interstrand crosslinks at equimolar
concentrations as BBR3610. Interestingly, cytoflow analysis of HCT116 cells showed that
BBR3610-DACH induced G1/S and G2/M cell cycle arrest with S phase depletion in contrast to
BBR3610 which showed initial accumulation in S phase followed by a classical G2/M arrest.
Immunoblotting revealed a stabilization of p53 and concomitant increased levels of p21 and p27
between 6-24 hr after treatment with BBR3610-DACH. Cell viability assays using MTT and
subsequent cytoflow analysis with p53 and p21 null cells indicated that the cytotoxicity profile of
BBR3610-DACH was p21 dependent and partially p53 dependent. However, increase in the
levels of cyclin E was observed with steady state levels of CDK2 and Cdc25A which are G1
phase regulators. The G2/M block was corroborated with decreased levels of cyclin A and cyclin
32

B1. Surprisingly, BBR3610-DACH induced G1 block appeared to be independent of the DNA
damage response effectors, ATM and ATR. Finally, both compounds induced apoptosis with
BBR3610-DACH showing a robust PARP-1 cleavage as early as 6 hr, independent of caspase3/7 cleavage. In summary, BBR3610-DACH is a DNA binding platinum agent with unique
inhibitory effects on cell cycle progression that could be further developed as a major
chemotherapeutic.
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INTRODUCTION:

Platinum drugs have been a mainstay of cancer therapeutics especially for the treatment of head
and neck, testicular, ovarian, lung, and colorectal cancers1, 2. The design of platinum drugs stems
from the basic structure of mononuclear platinum complexes, the efficacy of which is dictated by
three main pharmacological factors; cellular uptake, metabolic deactivation, and the type of
DNA adducts formed. Interaction of these drugs with cellular biomolecules like sulfur containing
glutathione and metallothionein, render them inactive before reaching their pharmacological
target, DNA3, 4. Subsequently, the multinuclear platinum compounds that are structurally
different from cisplatin, and exhibit a different mode of DNA binding, were developed to
circumvent the cellular resistance elicited toward the mononuclear compounds namely decreased
uptake and increased efflux and increased DNA repair. Also, since most of the useful platinum
compounds have the cis chemistry, the multi-nuclear platinum compounds showed a shift of
paradigm in the overall structure-activity relationship. Dinuclear platinum complexes containing
two reactive platinum centers were the first developed in this class of compounds to form longrange intrastrand and interstrand DNA crosslinks structurally different from adducts formed by
cisplatin or its second-generation analogues. The DNA binding ability, cytotoxicity, and
antitumor activity was further enhanced by introducing a third platinum within the
alkanediamine framework of the dinuclear complexes. The first prototype of this class, BBR3464
[{trans-PtCl(NH3)2}2µ-(trans-Pt(NH3)2(H2N(CH2)6NH2)]4+ (Fig 2-1A), was the only noncisplatin compound to have reached Phase II clinical trials. It was found to be cytotoxic in
cisplatin resistant cell lines and showed high efficacy in p53 mutant tumor cells5. However, a
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low therapeutic index, possibly due to increased metabolism and biotransformation reactions in
human plasma, rendered BBR3464 unsuitable for further evaluation6, 7.

In investigating the structure-activity relationship of the multinuclear compounds, especially the
trinuclear complexes, it was seen that the charged central platinum atom provided H-bonding and
an electrostatic pre-association with duplex DNA in the minor groove. Replacement of this
central platinum with linear polyamines resulted in second generation analogues of BBR3464
that retained its biological activity8. BBR3610 (Fig 2-1B), which was developed by replacing the
central platinum with a spermine linker, is one of the most cytotoxic platinum drugs with
nanomolar toxicity in gliomas and colon cancer cells. However, no improvement was observed
in the pharmacokinetic profile since like its predecessor, BBR3610 was also found to undergo
serum biotransformation leading to its degradation9. This was attributed to the substitution of the
Pt-Cl bond by a trans-influencing S donor (from thiol containing molecules), resulting in bridge
cleavage.

To improve the metabolic stability of the multinuclear compounds and also to circumvent the
irreversible plasma protein binding, different analogues of BBR3610 were developed by
modifying either the leaving groups or the carrier ligands. The first set of compounds were
derived by the replacement of the chloride ligands in BBR3610 with alkylcarboxylates, resulting
in a series of bis-platinum compounds, utilizing butyrate or capronate (CT-47518 and CT-47463
respectively, Fig 2-1C), with improved pharmacokinetic and pharmacodynamic profiles10. These
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compounds were found to overcome resistance due to defects in DNA mismatch repair and were
also found to be highly effective in cisplatin and oxaliplatin resistant cell lines. This was
subsequently followed by the development of another BBR3610 analogue containing the 1, 2diaminocyclohexane (DACH) ligand (Fig 2-1D). The chelating effect of the DACH ring
contributed to the increased metabolic stability of BBR3610-DACH in the presence of sulfur
containing compounds at physiological pH. In vitro studies showed this compound formed DNA
adducts that persisted longer, escaped DNA repair, and inhibited transcription11.

Deregulation of cell cycle progression is one of the key contributors toward cancer
development12. Exposure to DNA damaging agents induces G1/S or G2/M cell cycle arrest by
activating cell cycle checkpoint proteins that inhibit cyclin dependent kinases13. The resulting
cell cycle arrest can afford an opportunity for DNA repair and have negative effects on
apoptosis14. Thus, the pharmacologic disruption of the G2/M arrest induced by cytotoxic agents
can increase drug sensitivity. Much of the earlier studies on the cell cycle effects of platinum
drugs were carried out using cisplatin which showed a reduced DNA synthesis followed by S
phase accumulation and finally culminating in G2/M arrest. With few exceptions, mononuclear
and polynuclear platinum drugs, including BBR3464 and BBR3610 follow this trend of cell
cycle arrest.

Cell cycle studies of BBR3610-DACH suggest a point of divergence from the conventional
platinum drugs, and specifically its parental compound. BBR3610-DACH elicits a biphasic cell
cycle arrest in G1 and G2, with a complete depletion of cells in S phase. As our understanding of
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cell cycle arrest increases, the ability to accurately sequence chemotherapy based on phasespecific sensitivity can have a great impact on therapeutic approach in the treatment of human
cancers.
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Figure 2-1. Structures of the polynuclear platinum compounds
mentioned in the chapter.
(A) BBR3464; (B) BBR3610; (C) CT-47463 and CT-47518;
(D) BBR3610-DACH
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MATERIALS AND METHODS:

Chemicals. Cisplatin was obtained from Sigma, Cat# 479306. BBR3610 and BBR3610-DACH
were synthesized as discussed earlier. The stock solutions of platinum compounds were prepared
at the concentration of 1 mM in water and stored at -20°C. The ATM inhibitor, KU-60019, was
obtained from Selleck Chemicals.

Cell Culture and Drug treatments. The human colorectal cancer cell line, HCT116, and its p53
and p21 knockout derivatives (denoted as p53-/- and p21-/-) were cultured in RPMI 1640
(Invitrogen, Cat# 11875-093) supplemented with 10% fetal bovine serum (Quality Biologicals,
Cat# 110-001-101US) and 100 U/mL penicillin and 100 µg/mL streptomycin (Invitrogen, Cat#
15140). The mismatch repair proficient HCT116+chr3 cells (a kind gift from Dr. Richard
Boland) was cultured in IMDM (Invitrogen, Cat# 12440-053) supplemented with 10% fetal
bovine serum and 100 U/mL penicillin and 100 µg/mL streptomycin. Cells were maintained in
logarithmic growth as a monolayer in T75 tissue culture flask at 37°C in a 5% CO2 incubator.
For the drug treatment, the molar drug:cell ratio was kept constant by maintaining a seeding
density of 5X105 cells/10 mL medium.

Growth Inhibition Assay. 5000 cells/well in 100 µL were seeded in a 96-well plate and allowed
24 hr to attach. Cells were then treated with the drugs for 72 hr. Following drug removal, the
cells were treated with 0.5 mg/mL MTT reagent [(3, 4, 5-dimethylthiazol-2-yl)-2, 5-diphenyl
tetrazolium bromide; Sigma, Cat# M2128] in RPMI medium for 3 hr at 37°C. The MTT reagent
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was removed and 100 µL DMSO was added to each well. The plate was then incubated on a
shaker at room temperature in the dark. The spectrophotometric reading was taken at 570 nm
using a microplate reader.

Analysis of cell cycle distribution. HCT116, HCT116 p53-/-, HCT116 p21-/-, and HCT116 +
chr3 cells were seeded in 100 mm tissue culture dishes at a density of 5X105 cells per dish. After
24 hr, cells were treated with an equimolar dose of the drugs (20 µM) for 6, 24, and 48 hr
respectively. Both detached and floating cells were harvested at the different timepoints. One
million cells were then suspended in 1 mL of propidium iodide solution (3.8 mM sodium citrate;
0.05 mg/mL propidium iodide; 0.1% Triton X-100) with added RNaseB at a final concentration
of 7 Kunitz/mL and kept in the dark at 4°C. Cells were then analyzed using flow cytometry.

Flow Cytometry. A Becton Dickinson (San Jose, CA) FACSCanto II flow cytometer was used
for these studies. The argon ion laser set at 488 nm was used as an excitation source. Cells
having DNA content between 2N and 4N were designated as being in G1, S, and G2 phases
respectively. Twenty thousand events were acquired for each sample and the data obtained were
analyzed using the Modfit software.

Cell Synchronization studies. To obtain G0 synchronization, HCT116 cells were first seeded at
a density of 5X105 cells/10 cm dish and allowed 24 hr to attach. The cells were then serumstarved in medium containing 0.5% FBS for 96 hr. Flow cytometry analysis of synchronized
cells showed approximately 80% cells arrested in G0/G1 phase.
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Antibodies. The primary antibodies used are listed in Table 2-1 and were used at appropriate
concentrations as recommended by the manufacturer.

Immunoblotting. Following drug treatments, both floating and adherent cells were harvested,
washed once with ice-cold PBS and pelleted (10,000 rpm, 5 min, 4°C). The pellets were then
lysed in 50-200 µL SDS lysis buffer [62.5 mM Tris-HCl, pH 7.5, 5% glycerol, 4% SDS, 4%
complete protease inhibitor (Roche, Cat# 11873580001), 5% BME], passed through 21 gauge
needle 10-15 times on ice, and centrifuged (12,000 rpm, 20 min, 4°C). Protein concentrations
were determined by the Bradford Assay, resolved on 10%, 12%, or 4-20% gradient
polyacrylamide gels, and transferred to PVDF membrane (90 V, 75 min, 4°C). The membrane
was blocked in 5% non-fat dry milk in 1X Tris buffered saline containing 0.1% Tween-20 for
60-90 min. The membranes were then probed with the primary antibodies in blocking buffer
overnight at 4°C, followed by secondary antibody (anti-rabbit or anti-mouse) conjugated to
horseradish peroxidase (Cell Signaling, Thermo Scientific) for 1 hr at room temperature.
Chemiluminescent protein bands were visualized on X-ray films.

siRNA Transfection. ATR expression was down-regulated using the ON-Target plus Smart
Pool L-003202-00 and Non-targeting siGENOME control siRNA, D-001210-01-05 (Dharmacon,
Thermo Scientific). 50 nM siRNAs were transfected 24 hr after seeding of HCT116 cells using
Dharmafect 1 according to the manufacturer’s instructions.
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BrdU Incorporation Assay. To determine the percentage of cells in the S phase, the cells were
first treated with the drugs for the respective timepoints. They were then pulse-labeled with 10
µM BrdU for 3 hr prior to harvesting. The harvested cells were then fixed in 70% ethanol
overnight. Following fixation, the cells were incubated in 2.5 M HCl for 30 min and then in 0.1
M sodium borate for 2 min at room temperature. These were then blocked in PBS, 2% BSA,
0.1% Tween-20, RT, 1 hr, incubated with mouse anti-BrdU antibody (BD Biosciences) for 1 hr
and then probed with the secondary Alexa Fluor 488 rabbit anti-mouse antibody (Molecular
Probes, Invitrogen) for 1 hr. Finally, the cells were stained with propidium iodide and analyzed
by flow cytometry.

Comet Assay. Single cell gel electrophoresis or comet assay was carried out using a Trevigen kit
to detect and evaluate the DNA damage15. Briefly, HCT116 cells (1X105cells/mL) were plated in
35 mm or 60 mm dishes and allowed to attach for 24 hrs. The cells were then treated with
different concentrations of each drug for 1 hr. The medium was removed, the cells washed once,
and further incubated in fresh medium for 6 hrs. Cells were then harvested by scraping and
resuspended in 1 mL of ice-cold phosphate buffered saline (PBS, pH 7.4). Then, 50 µL of the
cell suspension was mixed with 500 µL of low melting agarose at 37°C, and 50 µL of this
mixture was spread on comet slides, and solidified in the dark for 30 mins at 4°C. The slides
were then treated with ice-cold lysis buffer in the dark for 1 hr at 4°C and then incubated in an
alkaline solution (pH>13) for 1 hr at room temperature to allow for alkaline unwinding.
Electrophoresis was carried out under alkaline conditions at 21 V, 300 mA, and 30 min at 4°C.
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Slides were washed twice with distilled water, once with 70% ethanol, and then allowed to dry
for 10 min at around 37-45°C. The slides were then stained with SYBR green for 5 min at 4°C.
Comet images were obtained using a fluorescence microscope (Olympus IX70). The comet
analysis was performed using the Comet Score software from TriTek Corporation.
The extent of crosslinking was expressed as the percentage decrease in tail moment and was
calculated using the formula:

% Decrease in tail moment = [1 – (TMdi - TMcu)/(TMci - TMcu)] X 100
where, TMdi is the tail moment of the drug treated irradiated samples, TMci is the tail moment of
the untreated irradiated samples, and TMcu is the tail moment of the untreated, unirradiated
samples. 40-50 comets were scored for each concentration and the reduction in comet tail length
and intensity was apparent within each sample.
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RESULTS:

BBR3610-DACH induces interstrand crosslinks in HCT116 cells. Polynuclear platinum
compounds are known to cause long-range intrastrand and interstrand crosslinks on DNA. In
this context, we investigated whether BBR3610-DACH induces interstrand crosslinks on the
DNA by utilizing the alkaline comet assay. Typical comet images are shown in Fig 2-2. In the
control, unirradiated, untreated HCT116 cells, no DNA damage was detected (Fig 2-2A).
Following irradiation with 15 Gy to introduce a fixed level of DNA strand breaks, the shorter
DNA fragments migrated from the bulk of DNA during alkaline electrophoresis to produce
comet tails (Fig 2-2B). When the irradiated cells were treated with 50-250 µM BBR3610DACH, a concentration-dependent decrease in the comet tail length and intensity was observed,
in comparison to irradiated controls (Fig 2-2C, D, E). Also, the comet heads were larger and had
higher intensity than the non-drug treated irradiated control possibly because of the retention of
more DNA in the head due to the drug induced interstrand crosslinks.

By quantifying the decrease in the moment of the comet tails, BBR3610-DACH-induced
interstrand crosslinks were compared to those formed by BBR3610 at similar concentrations and
were found to be similar, although BBR3610 showed a slightly higher level of crosslinks (Fig 22F).
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Figure 2-2. Comet images from HCT116 cells treated with BBR3610 or
BBR3610-DACH. Following irradiation (15 Gy) of untreated cells, distinct
comets were observed (B) in comparison to the untreated, unirradiated cells (A).
Cells were then treated with 50, 100, and 250 μM BBR3610 or BBR3610-DACH
for 1 hr followed by 6 hr drug free post-incubation for interstrand crosslink
formation. After irradiation of drug treated samples, comet tails with decreased
length and intensity could be observed due to the presence of the drug induced
interstrand crosslinks (C-E). All samples stained with SYBR green and observed
under a fluorescence microscope. Interstrand crosslink formation was
represented as percentage decrease in the tail moment ± SE. *p-value > 0.05 (F).
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BBR3610-DACH exhibits a significant anti-proliferative effect. BBR3610-DACH was
evaluated in HCT116 and in isogenic cell lines deficient in p53 or p21. Cells were exposed to the
platinum complex (0.78 – 50 µM) and the cytotoxicity was assessed using the MTT assay. In the
case of BBR3610, the cells showed an approximately 50% reduction in cell viability at 1-10 nM,
but were highly resistant to any further reduction (Fig 2-3A and Fig 2-4). The distinct biphasic
response seen with BBR3610 was not seen in cells treated with BBR3610-DACH (Fig 2-3A) and
as a result the IC50 (5 µM) was lower than that for BBR3610. However, the IC50 was higher in
the p53-deficient cells than in parental cells (Fig 2-3B) indicating a pivotal role of p53 in the
antiproliferative response. Surprisingly, in HCT116 p21-/- cells (Fig 2-3C), BBR3610-DACH
showed similar cytostatic effect as in the wild type cells. This could indicate that p21-mediated
cell cycle arrest in G1/S led to enhanced DNA repair and a reduction in cell death that roughly
balanced its direct anti-proliferative effect. The IC50 concentration for the three cell lines is
shown in Table 2-1.
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Figure 2-3. Cytotoxicity curves in HCT116 and isogenic cell lines. Cytotoxicity
curves showing the sensitivity of (A) HCT116; (B) HCT116 p53-/-; (C) HCT116 p21-/to BBR3610 and BBR3610-DACH determined by MTT assay following exposure to
micromolar concentrations of the drugs for 72 hr. Error bars indicate means ± SD from
three independent experiments.
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Figure 2-4. Percentage inhibition by BBR3610 plotted on a log scale. Error bars
indicate means ± SD from independent experiments.
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Table 2-1. Cytotoxicity of BBR3610-DACH in HCT116 and isogenic cell lines

* IC50 values are means ± SD from 3 separate experiments, each conducted in triplicate
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BBR3610-DACH induces G1 and G2 arrest in HCT116 cells. Following genotoxic stress
induced by antitumor agents, the p53 levels are stabilized resulting in induction of p21 which
mediates transient G1/S arrest, or apoptosis, depending on the damage incurred. The platinum
drugs such as cisplatin have been shown to activate the pathway leading to a G2 arrest16, 17.
Accordingly, treatment of HCT116 cells with 20 µM cisplatin causes S phase accumulation of
cells at 24 hr and finally a G2 arrest at 48 hr (Data not shown). However, treatment with 20 µM
BBR3610-DACH induced an early robust G1 and G2 phase arrest with a significant reduction in
S phase as compared to BBR3610 which showed only G2 arrest between 24-48 hr (Fig 2-5A, B).
This was corroborated by the BrdU incorporation assay wherein a steady decrease in S phase
population was seen following treatment with BBR3610-DACH (Fig 2-5C). Also, distinct cell
cycle effects of the two analogues were observed over a range of concentrations, with the
specific G2 block detectable with as low as 0.5 µM BBR3610 and G1 arrest with S phase
depletion being apparent with 5 µM BBR3610-DACH treatment (Fig 2-6). Thus, there are
qualitative differences between these compounds in cellular responses that cannot be ascribed to
difference in uptake, overall potency, or stability.

Concurrently, a stabilization of p53 protein level was seen in BBR3610-DACH-treated
cells, as early as 6 hr and continuing to 24 and 48 hr accompanied by an increase in p21 and p27
expression levels, which indicates the classical pathway being triggered for the G1/S phase arrest
and possibly the G2/M arrest (Fig 2-5D). However, the induction of p21 was found to be
independent of p53 (data not shown), indicating that in addition to p53 stabilization, other
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mechanisms are operating that lead to an increased expression of p21. The essential role of p53
in the G1/S phase arrest was confirmed by similar studies carried out in the HCT116 isogenic cell
line lacking p53 or p21 (Fig 2-7). However, in these cases, the G2/M arrest is independent of p53
and p21 indicating the role of other cell cycle proteins in triggering this pathway. Although
BBR3610 also induced both p53 and p21, the response was slower and less robust.
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Figure 2-5. BBR3610-DACH induces G1/S and G2/M cell cycle arrest in
HCT116 cells with robust S phase depletion. (A) Cells were treated with 20 µM
BBR3610 or 20 µM BBR3610-DACH and analyzed for cell cycle distribution using
propidium iodide. (B) Modfit analysis of G1, S, and G2 populations. Asterisks
indicate p-values obtained from t-test carried out between the treated and control
populations. *p-value < 0.05. **p-value < 0.005.
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Figure 2-5. BBR3610-DACH induces G1/S and G2/M cell cycle arrest in
HCT116 cells with robust S phase depletion. (C) BrdU staining assay showing
decrease in S phase population following treatment with 20 µM BBR3610-DACH as
compared to BBR3610 or cisplatin.
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Figure 2-5. BBR3610-DACH induces G1/S and G2/M cell cycle arrest in
HCT116 cells with robust S phase depletion. (D) HCT116 cells were treated with
20 µM BBR3610 or 20 µM BBR3610-DACH for 6, 24, and 48 hr. Representative
immunoblots are shown from two or three independent experiments.
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Figure 2-6. BBR3610-DACH induces G1 and G2 cell cycle arrest in a dose
dependent manner. HCT116 cells were treated with different concentrations of
BBR3610 or BBR3610-DACH for 24 hr and analyzed for cell cycle distribution using
propidium iodide.
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Figure 2-7. The cell cycle effect of BBR3610-DACH is dependent on the p53 and
p21 status in HCT116 cells. Following treatment with 20 µM BBR3610 or 20 µM
BBR3610-DACH, cell cycle distribution was analyzed using propidium iodide.
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BBR3610-DACH specifically targets G1 phase population of cells. To define precisely the
phase of the cell cycle where BBR3610-DACH exerts its anti-proliferative effect, we carried out
a “cell mapping “experiment. As shown in Fig 2-9, ~80% of the cell population was
synchronized in G1 phase after serum starvation (96 hr in 0.5% serum). The progression into S
phase was seen at 12 hr after release from the block. Immediately following release of the block,
treatment with 20 µM BBR3610 or BBR3610-DACH was carried out and cells were harvested at
8, 12, 16, and 24 hr respectively. The cells that were synchronized in G0/G1 continued to be
arrested following treatment with 20 µM BBR3610-DACH (Fig 2-8A). However, with
BBR3610 treatment, they progressed normally and halted in the S phase, possibly due to
collision of replication forks with interstrand crosslinks. This result shows that the cells are
specifically halted in the G0/G1 phase by BBR3610-DACH. To further confirm this finding, the
cells were released from the block and allowed to progress through G1 phase into S. A 4-hr
treatment with the drug in the early S phase, ~8 hr after release of block, resulted in a significant
blockade of cells at the G2/M phases in the case of BBR3610-DACH and a significantly delayed
accumulation in S phase in the case of BBR3610 (Fig 2-8B). These results corroborate the
observation with the asynchronous population of cells wherein a prominent G1/S and G2/M arrest
is seen following treatment with BBR3610-DACH, and further show that G1 accumulation in
BBR3610-DACH treated cells is due almost exclusively to a persistent and complete G1/S arrest,
and not to cells that successfully traversed mitosis to re-enter G1.
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Figure 2-8. BBR3610-DACH specifically inhibits the progression of G1 phase cells.
(A) HCT116 cells were synchronized in G0/G1 by serum starvation using 0.5% serum
for 96 hr. The cells were then released immediately into medium containing BBR3610
or BBR3610-DACH. Flow cytometric analysis was performed at different timepoints
to determine the progression of cell cycle after drug treatment. (B) HCT116 cells were
synchronized in G0/G1 by serum starvation, then released into medium and allowed to
progress into S phase. They were then treated with BBR3610 or BBR3610-DACH and
flow cytometric analysis was performed at different timepoints to determine the
progression of cell cycle following the PPC treatment.
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Figure 2-9. Cell Cycle Mapping. HCT116 cells were synchronized in G0/G1
phase by incubating in medium containing 0.5% serum for 96 hr. The cells were
then released into complete medium and harvested at specific timepoints to
check for entry into S phase.
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BBR3610-DACH induced S phase depletion is independent of ATM and ATR activation.
ATM and ATR are DNA damage sensor protein kinases that activate a signal transduction
cascade involving Chk1 and Chk2 and culminating in cell cycle checkpoints18. To check whether
the cell cycle perturbations elicited by BBR3610-DACH were ATM/ATR dependent, we
inhibited ATM/ATR activation by, (i) 2 mM caffeine treatment (inhibits both ATM and ATR),
(ii) KU-60019, a small molecule inhibitor of ATM (3 µM), and (iii) knockdown of ATR by 50
nM ATR-targeting siRNA.

Treatment with 2 mM caffeine, a pharmacological inhibitor of ATM/ATR, did not abrogate the
G2 arrest induced by BBR3610 treatment. However, following treatment with BBR3610-DACH,
the G1 phase arrest was maintained, but a reduction in the G2 population was observed (Fig 210A). In order to decipher this further, we individually inhibited ATM and ATR activation using
an ATM inhibitor and ATR-targeting siRNA respectively. Inhibition of ATM using 3 µM KU60019 did not abrogate the cell cycle effect elicited either by BBR3610 or BBR3610-DACH (Fig
2-10B), indicating that ATM activation was not a pre-requisite for cell cycle arrest by these
agents. Next, we investigated the involvement of ATR in the observed cell cycle effects induced
by the drug. ATR knockdown by siRNA (Fig 2-10D) allowed faster progression of BBR3610
treated cells through S phase to G2/M arrest, but did not relieve the G1 block in BBR3610-DACH
treated cells at all (Fig 2-10C). Instead a reduction in G2 phase cells was seen, as observed with
the caffeine treatment, suggesting partial abrogation of the G2/M arrest. The absence of ATR
activation by BBR3610-DACH was further confirmed by examining P-Chk1 levels19, which
were increased dramatically after 24 hr in the cells treated with BBR3610 (Fig 2-10E) or
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cisplatin (Fig 2-11A). This shows a significant S phase arrest following treatment with these
drugs which is then resolved, allowing cells to progress into the G2 phase. However, BBR3610DACH treatment did not induce any P-Chk1, indicating the absence of ATR activation, which is
consistent with the lack of delay in progression through S phase. In summary, ATM/ATR
activation is not a pre-requisite for the observed BBR3610-DACH induced S phase depletion in
comparison to BBR3610 wherein the S phase accumulation is abrogated following knockdown
of ATR (Fig 2-10C)
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Figure 2-10. BBR3610-DACH induced cell cycle arrest is independent of
ATM or ATR activity. (A) Effect of caffeine on BBR3610 or BBR3610DACH induced cell cycle arrest. Cells were pretreated with 2 mM caffeine for
1 hr and then treated with 20 µM BBR3610 or BBR3610-DACH for 10 hr or
24 hr as indicated. They were then analyzed for cell cycle distribution using
propidium iodide.

62

Figure 2-10. BBR3610-DACH induced cell cycle arrest is independent of
ATM or ATR activity. (B) Effect of ATM inhibition on BBR3610 or
BBR3610-DACH induced cell cycle arrest. Cells were pretreated with 3 µM
KU-60019, an ATM inhibitor, for 1hr and then treated with 20 µM BBR3610 or
BBR3610-DACH for 10 hr and 24 hr respectively. As a control, cells were also
treated with 0.05% DMSO (ATMi solvent).
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Figure 2-10. BBR3610-DACH induced cell cycle arrest is independent of
ATM or ATR activity. (C) Effect of ATR knockdown on BBR3610 or
BBR3610-DACH induced cell cycle arrest. Cells were transfected with 50nM
siRNA against ATR for 3 days. Drug was then added and the cells incubated for
24 hr.
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Figure 2-10. BBR3610-DACH induced cell cycle arrest is independent of
ATM or ATR activity. (D) Immunoblot showing ATR knockdown in
HCT116 cells using 50 nM siRNA in comparison to non-targeting siRNA
control and Dharmafect Reagent Control. DNA-PK was used as a loading
control. Blots are representative of three independent experiments.

65

Figure 2-10. BBR3610-DACH induced cell cycle arrest is independent of
ATM or ATR activity. (E) Immunoblot analysis of P-Chk1 levels in HCT116
cells following treatment with 20 µM BBR3610 or BBR3610-DACH. Blots are
representative of three independent experiments.

Figure 2-11. (A) Time course analysis of P-Chk1 levels in 20 µM cisplatin
treated HCT116 cells.
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Effect of BBR3610-DACH on G1/S and G2/M phase cell cycle regulators. The interaction of
cyclin-dependent kinases (CDKs) with their corresponding cyclins mediates the normal cell
cycle progression from G1 to S, S to G2, and G2 to M phases20. To assess their role in cell cycle
perturbations, we investigated the effect of BBR3610-DACH treatment on the protein levels of
G1 CDKs and cyclins. Immunoblot analysis revealed that 6, 24, and 48 hr treatment with
BBR3610-DACH which elicits a G1 arrest was accompanied by an increase in cyclin E which
normally accumulates in G1 and is degraded in S. CDK2 and Cdc25A were maintained at steady
state levels (Fig 2-12A), while phospho-Rb decreased markedly after 24 and 48 hr of drug
treatment. Thus, in BBR3610-DACH treated cells CDK2/cyclin E complexes presumably were
formed, but kinase activity was apparently suppressed by p21, resulting in Rb dephosphorylation
and G1 arrest. An increase in cyclin D1 and cyclin D3 was observed, which could be due to cells
exiting the G0 phase and getting arrested in G1. Also, the levels of cyclin A and cyclin B
drastically decreased after 24 and 48 hr of BBR3610-DACH treatment (Fig 2-12B), which may
result from p53 mediated suppression of their synthesis21, 22 and may contribute to G2 arrest.
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Figure 2-12. Effect of BBR3610-DACH on G1/S and G2/M regulators. Cells were
treated with 20 µM BBR3610 or BBR3610-DACH for 6, 24, or 48 hr. Protein
lysates were prepared and 30 µg protein was resolved on SDS-PAGE and detected
by probing the immunoblot with antibodies against (A) pRb, CDK2, Cdc25A, cyclin
E, cyclin D1 and cyclin D. β-actin was used as a loading control. Blots are
representative of three independent experiments.
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Figure 2-12. Effect of BBR3610-DACH on G1/S and G2/M regulators. Cells were treated
with 20 µM BBR3610 or BBR3610-DACH for 6, 24, or 48 hr. Protein lysates were
prepared and 30 µg protein was resolved on SDS-PAGE and detected by probing the
immunoblot with antibodies against (B) cyclin A and cyclin B1. β-actin was used as a
loading control. Blots are representative of three independent experiments.
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BBR3610-DACH induces an early PARP cleavage independent of caspase-3 and caspase-7
activation. Following prolonged arrest, damaged cells either recover or eventually undergo
programmed cell death or apoptosis. During this latter event, activated cysteine aspartate
proteases (caspases) primarily caspase-3 and caspase-7 cleave downstream substrates such as the
DNA repair protein, PARP, while activated caspase-6 mediates cleavage of nuclear lamins23, 24.
Treatment with BBR3610-DACH elicited a significant increase in PARP cleavage (~89 kDa) as
early as 6 hr (Fig 2-13). This was accompanied by a concomitant cleavage of both caspase-8 (45
kDa) which is a marker for the extrinsic pathway of apoptosis and caspase-9 (37 kDa and 35
kDa). However, no caspase-3 or caspase-7 cleavage was observed, suggesting a caspaseindependent PARP cleavage. For comparison and to rule out any technical errors, cells were
treated with 20 μM cisplatin as a positive control. A robust caspase-3/7 cleavage can be seen
between 24-48 hr of cDDP treatment (Fig 2-11B). There was no internucleosomal DNA
fragmentation in BBR3610-DACH treated cells, as analyzed by agarose gel electrophoresis
(Data not shown). Together, our results suggest that BBR3610-DACH induces a non-classical
apoptotic pathway.

70

Figure 2-13. BBR3610-DACH induces an early apoptotic response. Time course
analysis of caspase-8, caspase-9, full length and cleaved caspase-3, full length and
cleaved caspase-7, and cleaved PARP in HCT116 cells treated with 20 µM BBR3610
or 20 µM BBR3610-DACH for 6, 24, or 48 hr. β-actin was used as a loading control.
Arrow indicates the 37 kDa fragment of cleaved caspase-9. Blots are representative of
three independent experiments.
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Figure 2-11. (B) Time course analysis of cleaved caspase-3 and cleaved caspase-7
in HCT116 cells treated with 20 µM cisplatin for 6, 24, and 48 hr. β-actin was
used as a loading control. Representative immunoblots are shown from three
independent experiments. Asterisks indicate cleaved fragments of caspase-3 (17
and 19 kDa) and caspase-7 (20 kDa) respectively. Blots are representative of three
independent experiments.
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BBR3610-DACH-induced G1/S and G2/M arrest is independent of the DNA mismatch
repair system. DNA mismatch repair is a post-replication DNA repair mechanism which
removes the mismatch from newly synthesized daughter strands25, 26. Defects in mismatch repair
are one of the hallmarks of resistance to platinum drugs especially cisplatin. These defects allow
resistant tumor cells to tolerate DNA damage and complete DNA replication instead of
undergoing cell cycle arrest and apoptosis. Earlier reports have shown cells defective in the
mismatch repair system to be 1.5-2 fold resistant to cisplatin27. However, they do not show any
resistance to oxaliplatin, another mononuclear platinum compounds containing the DACH
ligand. This is attributed to the fact that the mismatch repair system recognizes cisplatin
diadducts more efficiently than the Pt-DACH diadducts28. In this context, we investigated
whether the disparate cell cycle effects elicited by BBR3610 and BBR3610-DACH were
dependent on the mismatch repair status of the cells. We used HCT116+chr3 cells wherein the
absence of the mismatch repair hMLH1 gene is complemented by the transfer of an additional
copy of chromosome 3, which carries the MLH1 gene29. Treatment of HCT116+chr3 cells with
BBR3610 or BBR3610-DACH resulted in cell cycle profiles similar to those of parental
HCT116 cells (Fig 2-14). Treatment with cisplatin elicited a classical G2/M arrest 24-48 hr after
drug treatment (Data not shown) that was similar for the two cell lines. This shows that similar to
cisplatin induced adducts, the DACH adducts are not recognized by the mismatch repair
machinery. Further experiments would be aimed toward deciphering whether another mismatch
repair gene, hMSH2 can recognize these adducts and elicit a repair response.
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Figure 2-14. The cell cycle response elicited by BBR3610 or BBR3610-DACH is
independent of the DNA mismatch repair. Wild-type HCT116 and hMLH1
complemented cells, HCT116+chr3, were treated with 20 µM BBR3610 or BBR3610DACH for 6, 24, and 48 hr. They were then analyzed for cell cycle distribution using
propidium iodide.
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Table 2-2. Antibodies Used in this study
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DISCUSSION:

Platinum-based drugs constitute one of the major classes in the armamentarium of cancer
therapies. However, their use is often compromised by inherited or acquired drug resistance in
cells. Presence of thiol-containing compounds such as glutathione and metallothionein is one of
the major factors contributing toward platinum drug inactivation3, 4. The dinuclear platinum
compound, BBR3610-DACH, used in this study, was previously shown to be resistant to
metabolic decomposition by glutathione. Subsequent in vitro studies showed the DNA adducts
formed by BBR3610-DACH persisted longer, escaped DNA repair, and inhibited RNA pol II
transcription much more efficiently than cisplatin adducts11. Taking these aspects into
consideration, the primary aim of this paper was to decipher the cellular effects elicited by
BBR3610-DACH in colorectal cancer cells.

Most of the polynuclear platinum compounds exhibit their anti-proliferative effect via a classical
G2/M cell cycle arrest mechanism. In the present study, BBR3610 induced a G2/M arrest
between 24-48 hr of treatment in HCT116 cells (Figure 2-5A). An identical profile was also
seen in glioma cells wherein BBR3610 induces an early G2/M arrest and autophagy subsequently
culminating in apoptosis30. However, BBR3610-DACH showed an interesting deviation from the
expected results wherein a biphasic G1/S and G2/M cell cycle arrest was seen with a robust
decrease in S phase (Figure 2-5A-C) after 24 hr drug treatment.
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DNA damage activates the tumor suppressor protein p53 which plays a crucial role in eliciting a
potent cell cycle arrest in both G1 and G2 phases of the cell cycle31. Platinum compounds target
and damage DNA which leads to activation and stabilization of p53. As expected, treatment with
both BBR3610 and BBR3610-DACH showed an increase in p53 levels, with BBR3610-DACH
showing more robust p53 stabilization after 24 hr, accompanied by increased levels of its
transcriptional target, p21. The role of p21 in conferring the aforementioned cell cycle effect was
confirmed in experiments with isogenic HCT116 p21-/- cells wherein the drug treatment failed
to arrest the normal G1 to S phase transition. However, the cells arrested in G2 phase, indicating
that p21 is not required for the drug mediated G2 arrest. Interestingly, similar set of experiments
with HCT116 p53-/- cells indicated a delayed S phase progression culminating in a late G2 arrest.
Binding of p21 to the proliferating cell nuclear antigen (PCNA) in p53-/- cells causes both G1
and G2 arrest32. Interestingly, in HCT116 p53-/- cells, we see increased expression of p21
following treatment with both BBR3610 and BBR3610-DACH (data not shown), possibly
pointing to a p53-independent mechanism for induction of p21 in eliciting bimodal cell cycle
arrest after treatment with platinum drugs.

One of the key features that distinguish polynuclear platinum complexes (PPC) from its
mononuclear counterparts is the formation of long range DNA intrastrand and interstrand
crosslinks. It is known that although some of the PPC-induced crosslinks cause conformational
changes in DNA, they are not recognized by many of the DNA binding proteins and repair
proteins that bind to adducts formed by cisplatin or its congeners. Earlier work using plasmid
DNA has shown that both BBR3610 and BBR3610-DACH form a high proportion of interstrand
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crosslinks (23% and 26% of total adducts respectively). Interstrand crosslinks are considered to
be highly toxic, since like DNA double strand breaks, they affect both strands of DNA, and can
irreversibly block major DNA transactions like replication, transcription, and recombination33, 34.
Similar to the in vitro studies, a significant amount of interstrand crosslinks were induced in
cells, as detected and analyzed by the comet assay (Figure 2-2). Thus, while it is likely that the
intracellular effects observed after treatment with these compounds are a direct consequence of
the crosslinks formed, there are no obvious qualitative or quantitative differences in adducts
formed that would explain the dramatic differences in cellular effects of BBR3610 and
BBR3610-DACH.

Ataxia Telangiectasia Mutated (ATM) and Ataxia Telangiectasia and Rad3-related (ATR) are
members of the PI3K-like family of serine/threonine protein kinases playing critical roles as
DNA damage sensors and contributing toward cell cycle arrest, DNA repair, and apoptosis
induction18. The role of ATR in sensing stalled replication forks owing to the presence of DNA
interstrand crosslinks caused by platinum drugs has been demonstrated earlier. Initial
experiments with caffeine (pharmacological inhibitor of both ATM/ATR), the ATM inhibitor
KU-60019, and ATR knockdown using siRNA showed that BBR3610-induced cell cycle arrest
was ATM-independent but ATR-dependent (Figure 2-10A-E). ATM activation occurs in cells
exposed to ionizing radiation like X-rays leading to the formation of DNA double strand breaks,
activating ATM which then phosphorylates serine 15 on p53 and stabilizes p53 levels35. In the
case of BBR3610, the crosslinks formed by the compound could be leading to DNA double
strand breaks due to a potential transcriptional arrest, which is then detected by ATM. Also,
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following BBR3610 treatment, the observed S phase accumulation at 24 hr could be possibly due
to replication fork arrest which is subsequently recognized by ATR which then activates P-Chk1
(Figure 2-10E). However, after 24 hr treatment, BBR3610-DACH induced a p53-dependent but
ATM- or ATR-independent G1 and G2 arrest, but the exact mechanism behind the dual phase
arrest is not known. Although increase in P-Chk2 levels (data not shown) is seen after BBR3610DACH treatment, the absence of S phase accumulation (Figure 2-5C) and ATR activation
(Figure 2-10E) excludes the possibility of known mechanisms of adduct recognition and
suggests a novel mechanism which detects DNA adducts directly and causes the recruitment of
DNA damage checkpoints and cell cycle arrest proteins36.In this context, it has been reported
earlier that adducts formed by the mononuclear platinum compound, oxaliplatin containing a
DACH ligand, is not recognized by ATR which points out to the fact that probably DACH
adducts are not recognized by the conventional DNA damage checkpoints37.

The normal progression through the different phases of the cell cycle depends on the pivotal
interaction of cyclin dependent kinases (CDKs) with the cyclins. In our study, the steady state
levels of CDK2 and Cdc25A remain unchanged while the level of cyclin D1 increases at 48 hr of
BBR3610-DACH treatment (Figure 2-12A), in comparison to BBR3610. A possible explanation
for the increased cyclin D1 levels could be due to the cells exiting the G0 phase and getting
arrested in G1. Interestingly, an increase in cyclin E levels is observed which could be a result of
a small subset of cells escaping the G1 arrest and entering into S phase. Earlier studies with
fibroblasts have shown an increase in the levels of cyclin D1 in cells undergoing replicative
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senescence38. It remains to be determined whether treatment with BBR3610-DACH could be
triggering the cancer cells to undergo a state of drug induced cellular senescence.

The G2-M transition is primarily governed by the activities of cyclin A and cyclin B. Following
treatment with BBR3610-DACH, a robust decrease in levels of both cyclins (Figure 2-12B) is
observed, indicative of a possible mitotic catastrophe. Treatment of HepG2 cells with 5fluorouracil or methotrexate reduced cyclin B2 mRNA levels accompanied with increased p53
levels22. Likewise, DLD-1 colorectal cancer cells harboring a p53 mutation showed decreased
cyclin B1 and B2 mRNA levels after expression of a wild-type p5322. On a similar basis,
stabilization of p53 following BBR3610-DACH treatment could be interfering with the
transcription of cyclin B or cyclin A21 since the latter consists of a p53 binding site in the 5’
untranslated region.

Earlier reports have shown that p53 could be activated independent of DNA damage especially
during metabolic stress. A p53-dependent G1 arrest is observed following depletion of nucleotide
pools caused by antimetabolites39. Experiments with synchronized cells show the G1 population
to be more sensitive toward BBR3610-DACH treatment (Figure 2-8). In this context, it would
be interesting to determine whether BBR3610-DACH could be acting as nucleotide biosynthesis
inhibitor, wherein p53 function helps maintain genomic stability by preventing the G1 to S phase
transition, in response to metabolic stress. Also, a cell cycle profile similar to that of BBR3610DACH has been reported in breast cancer cells treated with microtubule depolymerizing agents
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or in replicatively senescent cells, emphasizing the fact that BBR3610-DACH might be targeting
cellular components other than DNA40.

Cells arrested in different phases of the cell cycle for prolonged periods of time eventually
undergo cell death. In our study, BBR3610-DACH causes both caspase-8 and caspase-9
activation, similar to the parental compound BBR3610 or cisplatin (data not shown). Also, a
caspase independent PARP-1 cleavage (Figure 2-13) is observed which indicates the possible
involvement of cathepsins or TGF-β activation41. Since this effect is mechanistically different
from other platinum based compounds, it would be interesting to decipher whether this activity is
specific to compounds harboring a polyamine linker like spermine (BBR3610, BBR3610DACH) or spermidine (BBR3571). In this paper, we have not looked at the mitochondrial
disruption (loss of ΔΨm, permeability transition, cytochrome C release) following drug
treatment and which would be likely aspects to be considered for future studies.

In summary, BBR3610-DACH induces DNA interstrand crosslinks, eventually leading to a dual
mode of cell cycle arrest, and apoptotic induction. Since this compound exhibits significant antiproliferative activity and also has been shown previously to be metabolically stable to
nucleophilic attack, it would be an ideal candidate to be developed further and tested for clinical
trials. Also, it shows a promising paradigm shift for the structure-activity relationship of novel
platinum based compounds, wherein a ligand modification in the original compound, BBR3610
yields a structurally similar compound with a different pharmacokinetic and pharmacological
profile.
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CHAPTER 3

The platinum-intercalator conjugate, Trans-4-NBD, exhibits a
mechanistic behavior in cells similar to cisplatin:
Cytotoxicity, cell cycle arrest, DNA damage, and apoptosis

ABSTRACT:

Cisplatin has been one of the primary drugs utilized in the treatment of a variety of malignancies
like ovarian, colorectal, testicular, head, neck, and bladder cancers etc. However, recently, a
number of transplatinum compounds have been shown to be clinically active. The current work
explores the activity of a novel trans-NBD compound of structure trans-[PtCl2 (N-NBD) X
(NH3)] where X is butane-1,4-diamine, on the growth and viability of HCT116 human colorectal
carcinoma and A2780 human ovarian carcinoma cells, in addition to its possible mechanisms of
cytotoxicity. Comet analysis indicated that trans-4-NBD formed interstrand crosslinks at
equimolar concentrations as cisplatin in HCT116 cells. Cell cycle analysis in HCT116 shows a
significant G2 arrest at 24 and 48 hr of drug treatment whereas in A2780 cells, following 9 μM
(IC90) drug treatment after 24 hr, there is a small elevation in the number of cells in S-phase
which eventually recedes after 48 hr. We observed a marked increase in p53 protein levels in
both HCT116 and A2780 cells followed by an increase in p21 protein level. Both intrinsic as
well as extrinsic pathways of apoptosis are induced via activation of caspase-8, caspase-9, and
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caspase-3 and concomitant PARP cleavage. Also, a time-dependent activation of γ-H2AX is seen
which might be indicative of DNA damage response triggered following the formation of double
strand DNA breaks. In summary, trans-4-NBD is an active derivative of the therapeutically
inactive transplatin, showing cellular mechanisms similar to cisplatin.
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INTRODUCTION:

Platinum-based anti-cancer agents like cisplatin, carboplatin, and oxaliplatin have been highly
effective chemotherapeutics against a wide range of malignancies like testicular, ovarian, breast,
colorectal, head and neck, bladder cancers etc1-4. The cytotoxic activity of these platinum
compounds is attributed to their ability to form toxic bifunctional 1,2-intrastrand crosslinks
between the N7 atoms of guanine bases on DNA, inhibiting important DNA transactions like
replication, transcription, and recombination5-8. However, transplatin, the trans isomer of
cisplatin, is therapeutically inactive, since the trans geometry prevents the formation of 1, 2intrastrand crosslinks9-11. Eventually, the focus was shifted toward activating the trans geometry12,
13

to develop compounds with cytotoxicity greater than transplatin and similar to or greater than

cisplatin. These compounds were synthesized by replacing the NH3 ligand of transplatin with
planar heterocyclic ligands like pyridine, thiazole, quinoline, etc14,

15

. Additionally, these

complexes were found to be effective in cisplatin and oxaliplatin-resistant cell lines

,

16

suggesting a mechanistic difference in activity as compared to the clinically approved platinum
compounds.

Platinum compounds exhibiting a dual mode of DNA binding through the use of DNA
intercalators have been explored earlier17. These compounds interact with DNA through
conventional crosslinking and intercalation. Some of these compounds have been designed
earlier that utilized aromatic intercalators like anthraquinone18 and other cytotoxic moieties.
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Also, some of the intercalators employed are fluorophores that allow the visualization of
intracellular distribution of platinum drugs and their subsequent trafficking. One such
fluorophore, NBD (4-Chloro-7-nitrobenzofurazan), was recently used in the synthesis of a
fluorescent derivative of the polynuclear platinum compound, TriplatinNC19. Previously,
cisplatin derivatives containing the FITC or Alexa tags have been developed which unfortunately
exhibited biological properties of the tags utilized rather than the platinum compound itself20, 21.
The advantage of NBD is that it avoids difficult chemical modifications and involves direct
addition to the primary amine on the platinum compounds, giving analogs mimicking the
parental compound. Also, NBD by itself is inactive and exhibits fluorescent properties only
when it comes in contact with aliphatic amines or thiol compounds.

In this paper, we have reported the cytotoxic activity and cellular mechanism of a novel
transplatinum compound, trans-4-NBD (Fig 3-1). Interestingly, treatment of HCT116 and A2780
cells with trans-4-NBD showed similar cytotoxicity and biological properties to that of cisplatin,
suggesting a paradigm shift in the structure-activity relationship of platinum compounds.
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Figure 3-1. Stuctures of: (A) Cisplatin; (B) Transplatin; (C) Trans-NBD
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MATERIALS AND METHODS:

Chemicals:
Synthesis of the N-(7-nitro-2,1,3-benzoxadiazol-4-yl) butane-1,4-diamine 4-NBD Ligand.
BOC–diaminoethane/BOC–diaminobutane/BOC–diaminohexane was dissolved in ethanol
containing a 10% w/w of Na2CO3, and NBD-Cl was added. The mixture was stirred at room
temperature overnight, then water was added and the product was extracted with diethyl ether.
The organic phase was washed with brine, dried over Na2SO4 and purified by flash
chromatography (CHCl3: EtOAc, 75:25). The BOC protecting group of the purified intermediate
was removed by using trifluoroacetic acid (2 ml) at room temperature. After the mixture had
been stirred overnight, excess TFA was evaporated, and the oily product was treated with diethyl
ether to yield the trifluoroacetate salt as orange crystals. The compound was neutralized by
dissolving it in a mixture H2O/Ethanol 1:1 and addition of 1 equivalent of NaOH. The neutral
ligand was then extracted with CH2Cl2. The organic fractions were dried over K2CO3 and the
solvent removed under vacuum. The product was dried under vacuum overnight. The absence of
TFAcetate was confirmed by 19F NMR.

Synthesis of Trans-[PtCl2 (N-NBD) butane-1,4-diamine)(NH3)] (Trans4-NBD). Cisplatin (26
mg, 0.087 mmol) was suspended in 5 ml of deionized water and one equivalent of AgNO3 was
added. The mixture was stirred at 45ºC for 4.5 hr, and then cooled to 5ºC for 2 hr to allow full
precipitation of AgCl. The silver white salt was double filtered through a nylon membrane
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with a porous size of 0.45 µm. To that pale yellow filtrate, the amino ligand was added (19.34
mg, 0.087 mmol). That solution was stirred at room temperature overnight, and then filtered. 1.5
mL of HCl 37% was added and the resulting solution was stirred at 75ºC for 5 hr. The orange
clear solution was concentrated under vacuum until a precipitate appeared (~ 3 ml) and then
cooled to 5ºC to complete the precipitation of the final product. The orange powder was filtered,
washed with ice-cold water, ice-cold ethanol and ether, and then dried under vacuum for 24
hours. 1H NMR D2O δ (ppm): 8.36(d, 1H); 6.23 (d, 1H); 3.49 (m, 2H); 2.91 (m, 2H); 1.69 (m,
4H).

195

Pt NMR D2O δ (ppm): 2158(s). EA calculated for C10 H16 N6 O3 Pt Cl2: C, 22.53; H,

3.03; N, 15.75. Found: C, 22.16; H, 3.10; N, 15.65.

Cisplatin was obtained from Sigma, Cat# 479306. BBR3610 and BBR3610-DACH were
synthesized as discussed earlier. The stock solutions of platinum compounds were prepared at
the concentration of 1 mM in water and stored at -20°C.

Cell Culture and Drug treatments. The human colorectal cancer cell line, HCT116 and
isogenic HCT116 p53-/-, and the ovarian carcinoma cell line, A2780 were cultured in RPMI
1640 (Invitrogen, Cat# 11875-093) supplemented with 10% fetal bovine serum (Quality
Biologicals, Cat# 110-001-101US) and 100 U/mL penicillin and 100 µg/mL streptomycin
(Invitrogen, Cat# 15140). Cells were maintained in logarithmic growth as a monolayer in T75
tissue culture flask at 37°C in a 5% CO2 incubator. For the drug treatment, the molar drug:cell
ratio was kept constant by maintaining a seeding density of 5X105 cells/10 mL medium.
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Growth Inhibition Assay. 5000 cells/well in 100 µL were seeded in a 96-well plate and allowed
24 hr to attach. Cells were then treated with the drugs for 72 hr. Following drug removal, the
cells were treated with 0.5 mg/mL MTT reagent [(3, 4, 5-dimethylthiazol-2-yl)-2, 5-diphenyl
tetrazolium bromide; Sigma, Cat# M2128] in RPMI medium for 3 hrs at 37°C. The MTT reagent
was removed and 100 µL DMSO was added to each well. The plate was then incubated on a
shaker at room temperature in the dark. The spectrophotometric reading was taken at 570 nm
using a microplate reader.

Analysis of cell cycle distribution. HCT116 and A2780 cells were seeded in 100 mm tissue
culture dishes at a density of 5X105 cells per dish. After 24 hr, cells were treated for 6, 24, and
48 hr with an equimolar dose of the drugs (20 µM) for HCT116 cells or (9 µM) for A2780
respectively. Both attached and floating cells were harvested at the different timepoints. One
million cells were then suspended in 1 mL of propidium iodide solution (3.8 mM sodium citrate;
0.05 mg/mL propidium iodide; 0.1% Triton X-100) with added RNaseB at a final concentration
of 7 Kunitz/mL and kept in the dark at 4°C. Cells were then analyzed using flow cytometry.

Flow Cytometry. A Becton Dickinson (San Jose, CA) FACSCanto II flow cytometer was used
for these studies. The argon ion laser set at 488 nm was used as an excitation source. Cells
having DNA content between 2N and 4N were designated as being in G1, S, and G2 phases
respectively. Twenty thousand events were acquired for each sample and the data obtained were
analyzed using the Modfit software.
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Immunoblotting. Primary antibodies used were p53 (Cell Signaling, Cat # 9282), p21 (Cell
Signaling, Clone 12D1, Cat # 2947), caspase-8 (Cell Signaling, Clone 1C12, Cat # 9746),
caspase-9 (Cell Signaling, Cat # 9502), Caspase-3 (Cell Signaling, Cat # 9662), Cleaved PARP
(Cell Signaling, Cat # 9541), and β-actin (Cell Signaling, Clone 13E5, Cat # 4970). Following
drug treatments, both floating and adherent cells were harvested, washed once with ice-cold PBS
and pelleted (10,000 rpm, 5 min, 4°C). The pellets were then lysed in 50-200 µL SDS lysis
buffer [62.5 mM Tris-HCl, pH 7.5, 5% glycerol, 4% SDS, 4% complete protease inhibitor
(Roche, Cat# 11873580001), 5% BME], passed through 21 gauge needle 10-15 times on ice, and
centrifuged (12,000 rpm, 20 min, 4°C). Protein concentrations were determined by the Bradford
Assay and proteins were resolved on 10%, 12%, or 4-20% gradient polyacrylamide gels, and
transferred to PVDF membrane (90 V, 75 min, 4°C). The membrane was blocked in 5% non-fat
dry milk in 1X Tris buffered saline containing 0.1% Tween-20 for 60-90 min. The membranes
were then probed with the primary antibodies in blocking buffer overnight at 4°C, followed by
secondary antibody (anti-rabbit or anti-mouse) conjugated to horseradish peroxidase (Cell
Signaling, Thermo Scientific) for 1 hr at room temperature. Chemiluminescent protein bands
were visualized on X-ray films.

Comet Assay. Single-cell gel electrophoresis or comet assay was carried out using a Trevigen
kit to detect and evaluate the DNA damage. Briefly, HCT116 cells (1X105cells/mL) were plated
in 35 mm or 60 mm dishes and allowed to attach for 24 hr. The cells were then treated with
different concentrations of each drug for 1 hr. The medium was removed, the cells washed once,
and further incubated in fresh medium for 9 hr. Cells were then harvested by scraping and
94

resuspended in 1 mL of ice-cold phosphate buffered saline (PBS, pH 7.4). Then, the cell
suspension was mixed with low melting agarose at 37°C in 1:5 ratio (e.g. 50 µL of cell
suspension with 500 µL agarose), and 50 µL of this mixture was spread on comet slides, and
solidified in the dark for 30 min at 4°C. The slides were then treated with ice-cold lysis buffer in
the dark for 1 hr at 4°C and then incubated in an alkaline solution (0.6 g NaOH, 250 µL 2 mM
EDTA, pH>13) for 1 hr at room temperature to allow for alkaline unwinding. Electrophoresis
was carried out under alkaline conditions (12 g NaOH, 2 mL 500 mM EDTA, pH 8.0) at 21 V,
300 mA, and 30 min at 4°C. Slides were washed twice with distilled water, once with 70%
ethanol, and then allowed to dry for 10 min at around 37-45°C. The slides were then stained with
SYBR green for 5 min at 4°C. Comet images were obtained using a fluorescence microscope
(Olympus IX70).

Immunofluorescence. 2.5X104 HCT116 or A2780 cells were seeded on tissue culture treated 8well chamber slides (Lab Tek II) in 0.5 mL medium. Cells were then treated with 20 µM
cisplatin or trans-4-NBD for the indicated times. After removing the medium, cells were washed
with PBS and then fixed by incubating with 0.5 mL 3 % paraformaldehyde for 15 min at RT.
The cells were then washed with PBS and permeabilized with 0.5 % Triton-X/PBS for 10 min at
RT. The slides were then washed two times with 0.5 mL PBS/well followed by blocking in 1X
PBS/Casein buffer (Bio-Rad, Cat# 161-0783) for 2.5-3 hr. The primary antibody was diluted
appropriately in the blocking buffer, 0.5 mL was added to each well and allowed to incubate
overnight at 4°C on a rocker. Primary antibody used for immunostaining was anti-γ-H2AX
(Millipore) at 1:500 dilution. The primary antibody was then removed and the slides washed
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three times with PBS for 15 min each. The secondary antibody was diluted appropriately in the
blocking buffer, 0.5 mL added to each well and allowed to incubate for 3 hr at RT. The
secondary antibody used was Alexa Fluor 488 goat anti-mouse. The secondary antibody was
removed and the slides washed three times with PBS for 15 min each. The antibodies were then
fixed by treating each well with 0.5 mL 3 % paraformaldehyde for 15 min at RT, which was then
removed by 2 X 0.5 mL PBS washes. The chambers were removed with the tool provided with
the kit and the slides were then allowed to air dry (using the blower inside the tissue culture
hood). The slides were then mounted with Vectashield mounting medium containing DAPI (4´,
6-diamidino-2-phenylindole). A coverslip was placed over all the wells and sealed with clear nail
polish. Images were captured using Olympus fluoview 500 confocal microscope, using a 430 nm
diode laser with a 605 nm band pass filter (DAPI) and a 510 nm laser with a 530 nm band pass
filter (Alexa fluor 488).
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RESULTS:

Trans-4-NBD induces interstrand crosslinks. Mononuclear platinum compounds like cisplatin
form DNA interstrand crosslinks that constitutes 1 % of the total DNA adducts formed. Cellular
uptake and DNA binding studies showed that trans-4-NBD is taken up by the cells and binds to
DNA to the same extent as cisplatin in HCT116 cells (Martinez et al., unpublished data). In this
context, we investigated whether trans-4-NBD induces interstrand crosslinks on the DNA by
utilizing the alkaline comet assay. Three concentrations of trans-4-NBD were chosen (20, 50,
and 100 µM). Typical comet images are shown in Fig 3-2. In the control, unirradiated, untreated
HCT116 cells, no DNA damage was detected (Fig 3-2A). Following irradiation with 15 Gy to
introduce a fixed level of DNA strand breaks, the shorter DNA fragments migrated from the bulk
of DNA during alkaline electrophoresis to produce comet tails (Fig 3-2B). When the irradiated
cells were treated with trans-4-NBD, a concentration dependent decrease in the comet tail length
and intensity was observed, in comparison to irradiated controls (Fig 3-2C,D,E). Also, the comet
heads were larger and had higher intensity than the non-drug treated irradiated control possibly
because of the retention of more DNA in the head due to the drug induced interstrand crosslinks.
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Figure 3-2. Comet images from HCT116 cells treated with cisplatin or trans4-NBD. Following irradiation (15 Gy) of untreated cells, distinct comets were
observed in comparison to the untreated, unirradiated cells. Cells were then
treated with 20, 50, or 100 μM cisplatin or trans-4-NBD for 1 hr followed by a 9
hr drug free post-incubation for interstrand crosslink formation. After irradiation
of treated samples, comet tails with decreased length and intensity could be
observed due to the presence of the compound induced interstrand crosslinks. All
samples were stained with SYBR green and observed under a fluorescence
microscope.
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Trans-4-NBD exhibits a significant anti-proliferative effect. Trans-4-NBD was evaluated in
HCT116 and A2780 cells. These cells were exposed to the platinum complex (0.78 – 50 µM)
and the cytotoxicity was assessed using the MTT assay. Remarkably, both cell lines showed
sensitivity to trans-4-NBD in the same range as cisplatin with IC50 values of 7.6 µM and 2.3 µM
in HCT116 and A2780 cells respectively (Fig 3-3, Table 3-1).
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Figure 3-3. Cytotoxicity curves in (A) HCT116; (B) A2780 cells treated with 0.78 –
50 µM cisplatin or trans-4-NBD for 72 hr, determined by MTT assay. Error bars
indicate means ± SD from three independent experiments carried out in triplicates.
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Table 3-1. Cytotoxicity of cisplatin and trans-4-NBD
in HCT116 colorectal and A2780 ovarian cancer cell lines

* IC50 values are means ± SD from 3 separate experiments, each conducted in triplicate
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Trans-4-NBD induces G2 arrest in HCT116 cells and a transient S phase accumulation in
A2780 cells. Many DNA damaging drugs lead to stabilization of p53 protein levels which in turn
induces the transcription of p21, leading to G1/S arrest or apoptosis, depending on whether the
damage is repaired. The platinum drugs like cisplatin have been shown to activate the pathway
leading to a G2 arrest. Accordingly, treatment of HCT116 cells with 20 µM cisplatin induced a
transient S phase accumulation at 24 hr and finally a G2 arrest at 48 hr (Fig 3-4A). Treatment of
A2780 ovarian carcinoma cells with cisplatin has been shown earlier to cause S phase
accumulation following 24 hr drug treatment. In our studies too, we see a similar pattern of cell
cycle arrest following treatment with cisplatin. HCT116 or A2780 cells treated with trans-4NBD showed an identical cell cycle profile as cisplatin (Fig 3-4A, B). Concurrently, a time
dependent stabilization of p53 protein level is seen accompanied by an increase in p21
expression levels (Figure 3-5A, B), which indicates the classical pathway being triggered for the
G2/M arrest. This emphasizes the fact that both drugs might be activating the same set of cell
cycle checkpoints in different tumors.
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Figure 3-4. Trans-4-NBD induces G2 arrest in HCT116 cells and a transient S
phase accumulation in A2780 cells. (A) HCT116 cells treated with 20 µM cDDP or
20 µM trans-4-NBD and analyzed for cell cycle distribution using propidium iodide.
(B) A2780 cells treated with 20 µM cDDP or 20 µM trans-4-NBD and analyzed for
cell cycle distribution using propidium iodide.
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Figure 3-5. Trans-4-NBD induces stabilization of p53 with concomitant
upregulation of p21 in HCT116 and A2780 cells. (A) HCT116 cells were treated
with 20 µM trans-4-NBD for 18, 30, and 50 hr. Representative immunoblots are
shown from three independent experiments. (B) A2780 cells were treated with 20 µM
trans-4-NBD for 18, 30, and 50 hr. Representative immunoblots are shown from three
independent experiments.
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Trans-4-NBD induces both the extrinsic and intrinsic apoptotic pathways. Cytotoxic
transplatinum compounds have been shown earlier to induce apoptosis in different cell types.
One of the hallmarks of apoptosis is the activation of the cysteine serine proteases called
caspases. The extrinsic pathway triggers the activation of caspase-8 and the intrinsic or
mitochondrial dependent pathway activates caspase-9. Both pathways converge on the activation
of caspase-3 which then cleaves cellular substrates downstream. Treatment of HCT116 with 20
µM trans-4-NBD promoted cleavage of caspase-9 (Fig 3-6A) that probably indicates extensive
DNA damage triggering the intrinsic pathway. This was also accompanied by caspase-8 cleavage
indicating the activation of the death receptor-dependent apoptotic pathway. However, apoptotic
induction was found to be slightly lower compared to cells treated with 20 µM cisplatin for 55 hr
(Fig 3-6A). The induction of apoptosis was further proved by the activation of caspase-3 (Fig 36A) and the subsequent cleavage of its downstream substrate, PARP (Fig 3- 6C) which is a DNA
repair protein. Treatment of A2780 cells with trans-4-NBD showed a similar pattern of apoptotic
induction (data not shown). Also, similar experiments were carried out in the isogenic p53-null
HCT116 cells to check whether the apoptotic induction was dependent on the p53 status of the
cell. Interestingly, treatment of HCT116 p53-/- cells with 20 µM trans-4-NBD (Fig 3-6B)
showed identical apoptotic induction as the wild-type cells. This shows that trans-4-NBD
functions in a p53-independent manner and could prove to be a useful drug candidate against
cancer cells harboring mutant p53.
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Figure 3-6. Trans-4-NBD induces both the extrinsic and intrinsic apoptotic pathways.
(A) Time course analysis of caspase-8, caspase-9, and caspase-3 activation in HCT116
p53+/+ cells treated with 20 µM trans-4-NBD for indicated timepoints. Treatment with 20
µM cisplatin for 50 hr is used for comparison. β-actin was used as a loading control.
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Figure 3-6. Trans-4-NBD induces both the extrinsic and intrinsic apoptotic pathways.
(B) Time course analysis of caspase-8, caspase-9, and caspase-3 activation in HCT116 p53-/cells treated with 20 µM trans-4-NBD for indicated timepoints. Treatment with 20 µM
cisplatin for 50 hr is used for comparison. β-actin was used as a loading control.
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Figure 3-6. Trans-4-NBD induces both the extrinsic and intrinsic apoptotic pathways.
(C) Time course analysis of PARP cleavage in HCT116 p53+/+ and HCT116 p53-/- cells
treated with 20 µM trans-4-NBD for indicated timepoints. Representative immunoblots are
shown from two or three independent experiments.
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Trans-4-NBD triggers the formation of DNA double strand breaks. As seen earlier, trans-4NBD treatment caused the formation of interstrand crosslinks followed by a robust stabilization
of p53. To check whether there are other forms of DNA damage, we checked for the formation
of γ-H2AX foci, which is DNA damage repair protein recruited to sites harboring DNA double
strand breaks. HCT116 (Fig 3-7A) or A2780 (Fig 3-7B) cells treated with trans-4-NBD showed
a time-dependent induction of γ-H2AX foci, reaching maximum levels at 16-24 hr after drug
treatment. This shows that trans-4-NBD induces a variety of DNA damage responses mainly
due to the formation of interstrand crosslinks and DNA double strand breaks.
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Figure 3-7. Trans-4-NBD triggers the formation of DNA double strand breaks.
(A) Fluorescence microscopy of HCT116 cells treated with 20 µM cDDP or 20 µM
trans-4-NBD, showing an increase in γ-H2AX foci. (B) Fluorescence microscopy of
A2780 cells treated with 20 µM cDDP or 20 µM trans-4-NBD, showing an increase in
γ-H2AX foci.
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DISCUSSION:

The replacement of the NH3 ligand in transplatin with planar amines and intercalating
fluorophores has led to the development of transplatinum compounds with enhanced biological
activity. Earlier studies have shown that the transplanaramine complexes have similar
cytotoxicity as cisplatin and also retain their activity in cisplatin-resistant tumors22. Although
trans-4-NBD shows similar cytotoxicity as cisplatin in both HCT116 and A2780 cells, it remains
to be seen whether the trans-4-NBD discussed in this paper is effective in cisplatin or oxaliplatinresistant tumors. Also, one of the factors contributing toward the cytotoxicity of platinum
compounds is cellular accumulation. Cellular uptake studies (Martinez et al., unpublished data)
showed that trans-4-NBD accumulated in HCT116 or A2780 cells in a similar fashion as
compared to cisplatin. This was confirmed from the identical IC50 values of both drugs in
HCT116 (5 µM) and A2780 (0.5 µM). Interestingly, in earlier studies it has been reported that
cellular accumulation does not necessarily correlate to cytotoxicity of transplatinum complexes23.

DNA damage induced by cisplatin and the transplanaramine complexes cause a significant
stabilization of p53 in both HCT11624 and A2780 cells25. Likewise, treatment of HCT116 or
A2780 cells with trans-4-NBD showed an increase in p53 protein levels accompanied with
increased p21 levels. Like cisplatin, it showed a S phase accumulation in HCT116 after 24 hr and
a subsequent G2/M arrest at 48 hr whereas in A2780 cells, it showed an initial S phase
accumulation after 24 hr. Transplatinum complexes containing either a cyclohexylamine or a
propylamine ligand were shown earlier to cause a complete S phase blockade26. Therefore, it
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appears that most of the transplatinum complexes have a common mechanism of disrupting
cellular progression. The differential activation of various cell cycle checkpoints remains to be
elucidated following treatment with trans-4-NBD, although it might be mimicking cisplatininduced signal transduction.

The stabilization of p53 following trans-4-NBD treatment could be attributed to the DNA
interstrand crosslinking ability of the compound in cells. Since the cytotoxicity and cell cycle
effects elicited by trans-4-NBD are identical to cisplatin, it would be interesting to determine the
nature of DNA bending and unwinding since trans-4-NBD is structurally different from cisplatin.
Also, interstrand crosslinks formed by transplanaramine complexes have been shown to be poor
substrates for nucleotide excision repair27. On a similar basis, it would be exciting to see whether
the trans-4-NBD-induced interstrand crosslinks are recognized by the conventional repair
pathways and whether they are repaired to the same extent as cisplatin adducts.

The induction of apoptosis by transplatinum complexes has been verified in the past using
propidium iodide, annexin V binding, or caspase activation assays28. Treating HCT116 or A2780
cells with trans-4-NBD-induced both the extrinsic as well as intrinsic apoptotic pathways. This
could be due to the DNA damage caused by the compound via the formation of interstrand
crosslinks and DNA double strand breaks as seen from the increase in γ-H2AX foci. A similar
accumulation of γ-H2AX was seen in the transplanaramine complexes containing thiazole29.
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Trans-4-NBD provides a distinct advantage over cisplatin and other transplatinum complexes
wherein it is an excellent tool to visualize the distribution of the compound within the cells.
Experiments with a NBD-tagged polynuclear platinum compound, TriplatinNC, have shown a
distinct nucleolar localization of the compound, which ultimately is responsible for disruption of
rRNA transcription, leading to cell cycle arrest and apoptosis. Also, mononuclear platinum
complexes containing the NBD fluorophore30 were shown to trigger a non-apoptotic cell death
mechanism called paraptosis which occurred through extensive cytoplasmic vacuolization.
Although trans-4-NBD has been shown to induce apoptosis via activation of caspases and PARP
cleavage, cellular imaging studies will reveal distinct morphological changes induced after drug
treatment and whether it resembles classical apoptotic features or whether other mechanisms of
cell death are additionally involved.
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CHAPTER 4
TriplatinNC selectively targets the nucleolus
and disrupts rRNA transcription, which leads to
G1 phase cell cycle arrest and p53-independent apoptosis
Erica Peterson, Vijay Menon, Peyman Kabolizadeh, Brad Benedetti, Ralph Kipping,
John Ryan, Lawrence Povirk, Nicholas Farrell
(Paper in submission to Molecular Pharmaceutics)

ABSTRACT:

Cationic peptides, such as polyarginine, penetrate cellular membranes and localize specifically to
the nucleolar region of cells. TriplatinNC is a highly charged (+8), noncovalent derivative of the
phase II clinical platinum drug, BBR3464. TriplatinNC exhibits a distinct mode of high affinity
DNA interaction, increased cellular accumulation, and a significant cytotoxic profile in
mastocytoma, ovarian carcinoma, and cisplatin-resistant ovarian carcinoma cell lines. Here, it is
shown, through use of fluorescent-tagging and confocal colocalization experiments that
TriplatinNC rapidly localizes to the nucleolar compartment in HCT116 and A2780 cells. Due to
the cationic nature of TriplatinNC, it was considered likely to interact with negatively charged
nucleic acid components of the nucleolus, that is, ribosomal DNA/RNA.

32

P-metabolic labeling

of HCT116 cells determined that the production rate of 47S rRNA precursor transcripts is
drastically reduced as an early event after drug treatment, followed by a robust G1 cell cycle
arrest. Morphological characteristics of the apoptotic process are apparent within 24 hr,
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including: reduction in cell size, membrane blebbing, and cytosolic vacuolization. TriplatinNC
induces cleavage of mitochondrial-dependent and -independent initiators of apoptosis,
procaspase-9 and -8, followed by activation of the effector procaspase-3, and downstream target,
PARP-1. Furthermore, utilizing the isogenic HCT116 p53+/+ and p53-/- cell lines, it was
determined that these processes, are not dependent upon the presence of p53 protein. The results
presented here support a basis for selective targeting of rRNA processes as a strategy for p53independent induction of apoptosis in cancer cells and pave the way for an entirely new class of
platinum-based anticancer therapeutics.
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INTRODUCTION:

The increased proliferative rate of cancer cells relies on a concomitant upregulation of ribosomal
biogenesis in order to meet the cellular demands for protein synthesis (1-4). The biogenesis of
ribosomes is a coordinated process that largely takes place in the nucleolar compartment of the
cell. The nucleolus is formed around tandem arrays of more than 400 copies of ribosomal RNA
(rRNA) genes as they are transcribed, processed, and assembled into ribosomal subunits (5).
Recently, rRNA synthesis has emerged as a shared target of many anticancer agents (6). The
platinum-based drugs, oxaliplatin, and to a lesser extent, cisplatin, inhibit the transcriptional rate
of the 47S rRNA precursor transcript, while the antimetabolite, 5-fluorouracil (5-FU), disrupts
processing of the precursor into mature 28S, 18S, and 5.8S rRNA transcripts. In each case, the
effects are surprisingly early events; observed within hours after cell treatment. This implies that
inhibition of rRNA processes may be an early determinant of the antiproliferative activity of
these drugs. Of course, the effects of oxaliplatin, cisplatin, and 5-FU are not limited to rRNA
processes. They are nonselective, genotoxic drugs that modify, or incorporate into the total pool
of nucleic acid (7-9). Limiting genotoxic events by drug-targeting only nucleic acid within the
nucleolus and specifically, rRNA synthesis, is an interesting challenge for small molecule
therapeutics.

Unlike the nucleus and other membrane-bound organelles, there is no evidence of a membrane or
membrane-like structure separating the nucleolus from the surrounding nucleoplasm. In theory,
any soluble molecule could diffuse in and out of the nucleolar compartment. Because of
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sequence similarities in nuclear and nucleolar localization signals, it is currently accepted that
targeting of a specific molecule to the nucleolus results from its direct or indirect interaction with
components of the nucleolus, that is, ribosomal DNA and its transcripts (10). Positive charge is a
major factor in localization and retention of proteins to the nucleolus. Mutagenesis studies of
nucleolar proteins, such as nucleolin, fibrillarin, and the viral HIV TAT, determined that clusters
of the positively charged amino acids arginine, and lysine serve as nucleolar localization signals
(11, 12). Furthermore, poly-arginines and -lysines, containing more than six amino acids, rapidly
penetrate cellular membranes and localize specifically to the nucleolar region of cells (13-15).

TriplatinNC is a highly positively charged, (+8) non-covalent derivative of the phase II clinical
platinum drug, BBR3464 (16) (Fig. 4-1A, B).

The crystal and molecular structure of

TriplatinNC associated with a double-stranded B-DNA dodecamer 5′-d(CGCGAATTCGCG)2 at
1.2 Å resolution (PDB:2DYW), shows formation of phosphate clamps, a discrete third mode of
DNA binding, distinct from intercalation or minor groove binding. The phosphate clamp
involves two modes of DNA binding:

“backbone tracking” by following the phosphate

backbone of one strand, and "groove-spanning" across the minor groove to interact with both
strands (17). These interactions are uniquely mediated through hydrogen bonding, and are
analogous to the “arginine fork”, an important motif for protein-DNA interactions, where
positively charged guanidino groups of arginine, interact with negatively charged oxygens of
DNA phosphate (18-20). The polyarginine analogy has also allowed identification of heparan
sulfate proteoglycans as mediators of TriplatinNC cellular accumulation by pursuing
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the isostructural analogy of sulfate and phosphate and the accepted molecular mechanism of
polyarginine uptake (21). We have now extended the conceptual analogy of TriplatinNC as a
small molecule polyarginine mimic by examining its localization to the nucleolar compartment
within cells. This report examines the biology of the phosphate clamp and reveals remarkable
differences in the cellular localization pattern of TriplatinNC compared to cisplatin by comparing
the fluorophore-drug conjugates, TriplatinNC-NBD and its cisplatin-NBD analog (22).
TriplatinNC rapidly accumulates within the nucleolar region of the cell, and as an early event
upon cellular treatment there is a resulting decrease in the production rate of 47S rRNA
precursor transcripts. Further studies detailed in this report set a timeline of the subsequent
morphological, antiproliferative, and apoptotic events.
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Figure 4-1. Structures of (A) BBR3464 and (B) TriplatinNC. The noncovalent polynuclear
compound, TriplatinNC, is a direct structural analog of the Phase II drug BBR3464, where
the labile chloride ion is replaced by the amine group, NH2(CH2)6NH2.
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MATERIALS AND METHODS:

Drug Synthesis. Cisplatin was synthesized as previously described; [Wong, E.S.Y.;
Giandomenico, C.M., Patent No. 09678595]. TriplatinNC was synthesized as described
previously (16). The synthesis of TriplatinNC-NBD and Cisplatin-NBD are described later in
this chapter.

Cell Culture and Drug Treatments. HCT116p53+/+, HCT116 p53-/-, and A2780 cell lines
were cultured in RPMI 1640 (Invitrogen), supplemented with 10% calf serum (Atlanta
Biologicals) and 1% penicillin/streptomycin (Invitrogen). Cells were maintained in logarithmic
growth as a monolayer in T75 culture flasks at 37°C in a humidified atmosphere containing 5%
CO2. For drug treatment studies, unless otherwise noted, the molar drug: cell ratio was kept
constant by seeding 5x104 cells/mL media throughout.

Confocal Fluorescence Microscopy. 5x104 cells were seeded on chamber slides (Lab-Tek II) in
media. 24 hr after seeding, cells were treated with TriplatinNC-NBD or Cisplatin-NBD at the
indicated times and concentrations. After removing the media, cells are washed with PBS and
mounted as described below. For Immunofluorescence of fibrillarin, cells were permeabilized
with 0.5% Triton-X in PBS for 10 min. and blocked in PBS/Casein for 1 hr at room temperature.
1:200 dilution of primary antibody, anti-fibrillarin (cell signaling, clone C13C3) was added
overnight at 4°C. The primary antibody was then removed and wells were washed 4 times with
0.5 mL PBS for 15 min each followed by incubation with a 1:500 dilution of secondary antibody
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anti-rabbit IgG Alexa 647 conjugate (cell signaling) for 3 hr at room temperature. After
removing the secondary antibody, the wells are washed again 4 times with 0.5 mL PBS and
antibodies are then fixed with 3% paraformaldehyde for 15 min. at room temperature.
Paraformaldehyde is then removed by 2 X 0.5 mL washes. All slides were mounted in
VectaShield mounting medium containing DAPI (4’, 6-diamidino-2-phenylindole, Vector Labs)
and viewed using a Zeiss LSM 510 confocal microscope.

Flow Cytometry. HCT116 cells were drug treated for 6, 24, and 48 hr. 1x106 cells were
suspended in 1 ml of propidium iodide solution (3.8 mM sodium citrate; 0.05 mg/ml propidium
iodide; 0.1% Triton X-100) with added RNase B (7000 units/ml) and kept in the dark at 4°C.
Cells were analyzed by flow cytometry on a CoulterElite XL-MCL (Beckman Coulter). Twenty
thousand events were acquired and analyzed using Modfit software.

Metabolic Labeling and rRNA analysis. 2x105 HCT116 cells were grown in 6-well plates in 4
ml RPMI/10% FBS media for 24 hr. Cells were drug treated for 5 hr. For phosphate depletion,
complete media was replaced with phosphate-free DMEM/10% dialyzed FBS containing drug
and incubated for 30 min. before the addition of 15 µCi/ml
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P-orthophosphate (Perkin Elmer)

and further 30 min. incubation. Medium was again changed to RPMI/10% FBS drug-containing
medium for 3 hr and total RNA was isolated using RNeasy (Qiagen). RNA concentration was
determined using a Nanodrop. 1.5 µg of total RNA was separated on a 1% agarose-formaldehyde
gel. After electrophoresis, 28S rRNA quantities were visualized with Ethidium Bromide as a
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loading control. Gels were placed on Whatman paper and dried for 2 hr at 80°C under vacuum
suction. Dried agarose gels were exposed to X-ray film.

Electromobility

Shift

Assay.

2

nM

end-labeled

dsDNA

(24mer

5’-

GAAGGGGGGCTCTAAAAGGGGGTG-3’ containing the AdML TATA box.) was incubated
for 15 min. at 30°C with or without drug in a final volume of 10 µl reaction buffer (20 mM
Hepes-KOH, pH 7.9, 25 mM KCl, 10% glycerol, 0.025% NP-40, 100 µg/mL BSA, 0.5 mM
DTT, 0.1 mM EDTA, and 2 mM MgCl2). Where indicated, 100 ng rTBP (Santa Cruz) was added
to the reactions and was further incubated for 30 min. The reactions were separated by
electrophoresis in a 6% native polyacrylamide gel in 0.5X TBE buffer (45 mM Tris-HCl, 44 mM
boric acid, and 2 mM MgCl2). The gel was dried and exposed to X-ray film.

Growth Inhibition Assay. Cells were seeded in a 96-well plate at 5x103 cells/well in 100 µl
media and allowed 24 hr to attach. Cells were then drug treated for a period of 72 hr. After
removal of drug, the cells were treated with 0.5 mg/mL MTT reagent [(3,4,5-dimethylthiazol-2yl)-2,5-diphenyltetrazolium bromide; Sigma] in media for 3 hr at 37°C. The MTT reagent was
removed and 100 µl of DMSO was added to each well. The plate was then incubated on a shaker
at room temperature in the dark. The spectrophotometric reading was taken at 570 nm using a
microplate reader.
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Clonogenic Survival Assay. 2x104 HCT116+/+ and HCT116-/- cells were seeded in 3 ml of
medium in a 6-well plate. After 24 hr of incubation, cells were then treated with 20 µM drug for
a 24 hr period. 250 or 2500 cells were seeded into 10 cm dishes and allowed to grow for 10-14
days to form colonies. These were then fixed by methanol, stained by 0.1% crystal violet, rinsed
with water, and air dried. Colonies consisting of more than 50 cells were counted. Plating
efficiency and surviving fraction were determined for each drug.

Immunoblot Analysis. Primary antibodies used were p53 (Cell signaling, # 9282), p21 (Santa
Cruz, clone F-5), p27 (Cell signaling, clone SX53G8.5), total caspase-3 (Cell-signaling, 9662),
total caspase-8 (Cell signaling, clone IC12), cleaved caspase-9 (Cell signaling, #9501), cleaved
PARP (Cell signaling, # 9541), and β-Actin (Abcam, ab8226). After drug treatments, both
floating and adherent cells were harvested. Cells were washed with ice-cold PBS, repelleted,
and, resuspended in SDS lysis buffer (62.5 mM Tris-HCl, pH 7.5, 5% glycerol, 4% SDS, 4%
complete protease inhibitor (Roche), 5% BME). After homogenization, proteins were resolved
on 7.5-15% polyacrylamide gels, transferred to PVDF membrane, and blocked in 5% non-fat
milk at room temperature for 1 hr. The membranes were probed with primary antibodies
overnight, followed by secondary anti-rabbit, or anti-mouse antibodies conjugated to horseradish
peroxidase (Cell Signaling, Thermo Scientific). Chemiluminescent protein bands were visualized
on X-ray film.
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RESULTS AND DISCUSSION:

TriplatinNC rapidly accumulates within the nucleolus. To determine differences in the
cellular localization pattern of TriplatinNC compared to Cisplatin, each compound was labeled
with the small fluorophore, 7-nitrobenzoxadiazole (NBD) (22). The resulting drug-NBD
conjugates, Cisplatin-NBD and TriplatinNC-NBD (Fig. 4-2A), retain charge properties and cell
growth inhibition values (IC) comparable to that of the parent compounds (Fig. 4-3). Confocal
microscopy showed that TriplatinNC-NBD, but not Cisplatin-NBD, rapidly accumulates to
punctate regions of the nucleus in HCT116 colon carcinoma and A2780 ovarian carcinoma cell
lines (Fig. 4-2B, C). In co-localization studies, the distinct nuclear localization patterns of
TriplatinNC overlaps the signal of the commonly used nucleolar marker, Fibrillarin, a
ribonucleoprotein methyltransferase involved in the first steps of ribosomal RNA (rRNA)
processing (Fig. 4-2D). Due to this unique pattern of localization, and the charged nature of the
drug, it was considered that TriplatinNC was likely to interact with ribosomal DNA/RNA within
the nucleolus.
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Figure 4-2. Fluorescently-tagged TriplatinNC localizes to the nucleolus.
(A) Structures; Fluorophore conjugates Cisplatin-NBD and TriplatinNC-NBD. (B)
Confocal Microscopy; The cellular distribution of NBD-Cisplatin (green) in A2780
cells after 24 hr incubation in 10 µM drug. (C) NBD-TriplatinNC (green) in A2780
and HCT116 cells after 2 hr incubation with 20 µM drug, respectively. The DNA is
subsequently stained with DAPI (blue) as reference. (D) Colocalization (orange) of
NBD-TriplatinNC (green) with the nucleolar marker, fibrillarin (red), in HCT116 cells
after 4 hr incubation in 20 µM drug. Anti-fibrillarin signal was detected using a
secondary antibody conjugated to Alexa-fluor 647.
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Figure 4-3. MTT Assay; A2780 or HCT116 cells were treated with the indicated
concentration of drug for 72 hr. In each graph the drug-NBD derivative is denoted in dark
gray and the parent compound in light gray. (A) A2780 cells treated with TriplatinNCNBD and TriplatinNC. (B) HCT116 cells treated with TriplatinNC-NBD and
TriplatinNC-NBD. (C) A2780 cells treated with Cisplatin-NBD and Cisplatin. (D)
HCT116 cells treated with Cisplatin-NBD and Cisplatin. Percent Inhibition is calculated
as: 1-(N/N0), where N=treated samples and N0= untreated control samples. Data are
shown as mean ± S.D. representative of at least 2 independent experiments.
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As an early event, TriplatinNC disrupts the rate of rRNA transcription. Initiation of rDNA
transcription requires assembly of a specific multiprotein complex that binds to the rDNA
promoter containing RNA polymerase I (Pol I), and two Pol I specific transcription factors,
upstream binding protein (UBF), and the promoter selectivity factor complex, SL1 (23). The
binding specificity of Pol I at rDNA promoters is conferred by SL1 (24), comprised of the
transcription factor TBP (TATA-Box Binding Protein) and several auxiliary TBP-associated
factors (25, 26). The ability of TriplatinNC to inhibit TBP-DNA interactions was examined in
vitro using the Electromobility Shift Assay (EMSA). TriplatinNC reduced the TBP-DNA
complex by 50% using between 0.63 and 1.25 µM drug concentrations (Fig. 4-4A). These results
suggest that TriplatinNC has the ability to inhibit RNA transcription by physical inhibition of
DNA-binding proteins required for this process. This process is distinct from the effects of
covalently-binding platinum drugs (27-30).

To determine whether TriplatinNC affects the rate of rRNA transcription in vivo, HCT116 cells
were treated with varying drug concentrations for 5.5 hr, and then metabolically labeled
according to the scheme depicted in Fig. 4-4B. The 47S rRNA precursor transcript is
sequentially cleaved to yield the mature 28S, 18S, and 5.8S rRNAs. As cells are pulsed with 32Pradiolabeled orthophosphate for 30 min. followed by a 3 hr chase, the abundance of newly
formed 47S precursors, 32S intermediate cleavage products, and mature 28S and 18S rRNAs are
sufficiently labeled for visualization by autoradiography (6). It was evident that treatment of cells
with TriplatinNC inhibits the production rate of 47S rRNA precursor transcripts in a dose
dependent manner (Fig. 4-4B). It does not appear that TriplatinNC affects the rate of 47S rRNA
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processing, as the abundance of 32S, 28S, and 18S rRNAs decreases proportionally to that of the
precursor.

The transcriptional activity of rRNA genes has been shown to change in accordance with the cell
cycle (25). rRNA transcription levels are highest in S and G2 phases, nonexistent in mitosis, and
rebounding in G1 (26, 27). Therefore, it was important to consider whether the inhibitory effect
of TriplatinNC on the rate of rRNA transcription was direct, or if rRNA transcription levels were
merely downregulated as an indirect effect of changes within the cell cycle. The latter would be
likely if there were an increase in the population of cells in G1 (when rRNA levels are lower).
For this purpose, HCT116 cells treated with TriplatinNC were subjected to cell cycle analysis by
flow cytometry. In cells treated with 20 µM TriplatinNC [(IC90) (Fig. 4-3B)] for 6 hr, there were
modest changes that occurred within the cell cycle. The population of cells in G1 decreases
slightly from 37% to 30% compared to untreated control cells, while the population of cells
within S+G2 increases slightly from 63% to 70%. These results imply the disruption of rRNA
transcription is an early event of cellular treatment with TriplatinNC, and does not result from
changes in the cell cycle.
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Figure 4-4. TriplatinNC competitively inhibits TBP-DNA interaction and
interferes with rRNA transcription.
(A) EMSA; Lanes 3-9; 2 nM 32P-labeled DNA incubated with 0.08, 0.16, 0.31,
0.63,1.25, 2.5, and 5 µM drug, respectively, followed by 100 ng rTBP protein. Lane
2 is the ‘TBP/DNA complex’ positive control. Lane 1 is the ‘free DNA’ control
containing DNA only.
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Figure 4-4. TriplatinNC competitively inhibits TBP-DNA interaction and
interferes with rRNA transcription.
(B) 32P-Pulse/Chase Metabolic Labeling; Samples were treated with or without drug
according to the experimental outline. Lanes 1-8 were treated with 0.78, 1.6, 3.1,
6.3, 12.5, 25, 50, 100 µM drug, or without drug in lanes 1 and 2. 1.5 µg total RNA
was analyzed for each sample. Ethidium Bromide (EtBr) staining of 28S rRNA was
used as a loading control.
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At 24hr, TriplatinNC induces a G1 cell cycle arrest.

Anticancer therapeutics cause

proliferative arrest generally through induction of a classical signaling pathway (28). Central to
this pathway is the stabilization of p53 protein by serine/threonine kinases, followed by
transactivation of the cyclin-dependent kinase (CDK) inhibitor, p21. Increased protein levels of
p21 inhibit CDK activities resulting in cell cycle arrest. This pathway is induced by cisplatin,
which has been shown to arrest cells at the G2-checkpoint as an attempt to repair DNA damage
before cells enter mitosis (29, 30). In agreement with these studies, HCT116 cells treated with 20
µM cisplatin [(IC90), (Fig. 4-3D)] were shown to induce S-phase accumulation at 24 hr, and
finally G2 arrest at 48 hr (Fig. 4-6). Treatment of HCT116 cells with 20 µM TriplatinNC, on the
other hand, induced an earlier arrest in G1 at 24 hr continuing to 48 hr. The increase in the
number of cells in G1 was mostly at the expense of the proportion of cells undergoing DNA
replication in S-phase, which decreased 52% at 24 hr and 77% at 48 hr compared to the control.
(Fig. 4-5A, B). As expected, there is a substantial stabilization of p53 protein levels leading into
the G1 arrest at 12 and 24 hr after treatment with TriplatinNC (Fig. 4-5C). However, p21
expression levels are not concomitantly upregulated in the classical manner. Surprisingly, p21
protein expression levels decreased at 6 and 12 hr, and increase only to basal level at 24 hr.
Furthermore, the protein expression levels of p27, a similar CDK inhibitor with the potential to
cause cell cycle arrest (31), also decreased. These data suggest that the G1-arrest induced by
TriplatinNC may not depend on classical signaling events. The fact that TriplatinNC induces G1arrest in the HCT116 isogenic cell lines lacking either p53 or p21 (Fig. 4-7), furthers this point.
It is tempting to speculate that TriplatinNC may disrupt the cell cycle at G1, because S-phase has
the highest requirements for rRNA production (32). The consideration that G1-cyclin proteins
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and others may be synthesized in insufficient amounts to allow for the transition into S-phase is a
subject of continuing research.
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Figure 4-5. TriplatinNC induces G1 cell cycle arrest. (A) HCT116 cells
were treated with 20 µM TriplatinNC (IC90) for 6, 24, and 48 hr and analyzed
for cell cycle distribution using propidium iodide. (B) Modfit software analysis
of G1, S, and G2 populations. Data points are shown as mean ± S.D. of 2
independent experiments with 2 replicates per sample.
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Figure 4-5. TriplatinNC induces G1 cell cycle arrest. (C) HCT116 cells were
treated with 20 µM TriplatinNC for 3, 6, 12, and 24 hr. The levels of p53, p21,
and p27 were detected using western blotting. β-Actin is used as a loading
control. Representative immunoblots are shown from three independent
experiments.
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Figure 4-6. HCT116 cells treated with 20 µM cisplatin for 0, 24, and 48 hr.
They were then RNase B treated and analyzed for cell cycle distribution using
propidium iodide.
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Figure 4-7. HCT116, HCT116 p53-/-, and HCT116 p21-/- cells were treated with 20 µM
TriplatinNC for 0, 24, and 48 hr. They were then RNase B treated and analyzed for cell cycle
distribution using propidium iodide.
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TriplatinNC causes rapid proliferative arrest and cell death independently of p53 status. In
cells undergoing apoptosis, activated cysteine proteases, caspases-3, -6, -7, result in cleavage of
cytoskeletal proteins and fragmentation of nuclear DNA. These events result in visible changes
to the morphology of the cell including cell shrinkage, chromatin condensation, cytosolic
vacuolization, and membrane blebbing (33). Changes in physiology of HCT116 cells treated
with 20 µM TriplatinNC-NBD were visualized using confocal microscopy after 2, 10, and 30 hr
of treatment (Fig. 4-8A). After 10 hr of treatment, cells are much smaller in size and exhibit
prolific cytosolic vacuolization. After 30 hr of treatment, blebbing and disintegration of the outer
membrane is apparent.

Nearly all cancers harbor genetic defects that directly, or indirectly, inhibit normal proapoptotic,
or tumor suppressor functions of p53 (28). For this reason, we asked whether the absence of p53
affects the ability of TriplatinNC to effectively induce proliferative arrest and cell death.
HCT116 p53+/+ and p53-/- cells were treated with 20 µM cisplatin or TriplatinNC for 12, 24,
48, or 72 hr. Using the MTT assay, it was determined that the kinetics and extent of cisplatin
inhibition on cell growth was significantly limited in the absence of p53 (Fig. 4-8B). However,
the inhibitory effects of TriplatinNC on cell growth was unaffected by the absence of p53 protein
(Fig. 4-8B). In support of these results, we asked further whether the absence of p53 affects the
ability of TriplatinNC to inhibit colony-formation, or reproductive viability, using the clonogenic
survival assay. HCT116 p53+/+ and HCT116 p53-/- cells were treated with 20 µM TriplatinNC
for 24, 48, and 72 hr (Fig. 4-8C, Fig. 4-9). The percentage of cells that failed to replicate was
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determined as 69±6%, 88±2%, 92±7% after 24, 48, and 72 hr, respectively. There was no
significant difference in cells with or without p53.
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Figure 4-8. TriplatinNC causes rapid proliferative arrest and cell death.
(A) HCT116 cells were treated with 20 µM TriplatinNC for 2, 10, and 30 hr. Confocal
microscopy was carried out to observe morphological effects of apoptosis like reduction
in cell size, membrane blebbing, and cytosolic vacuolization (white arrows).
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Figure 4-8. TriplatinNC causes rapid proliferative arrest and cell death.
(B) Comparison of growth inhibition in HCT116 p53+/+ (light gray) and p53-/- (dark
gray) cells treated with 20 µM cisplatin or TriplatinNC was carried out using the MTT
assay. Percent Inhibition is calculated as: 1-(N/N0), where N=treated samples and N0=
untreated control samples. Data points are shown as mean ± S.D. of 2 independent
experiments with 3 replicates per sample. **p<0.05, ***p<0.005. (C) Clonogenic
survival assay was carried out to compare the reproductive viability in HCT116 p53+/+
cells and p53-/- cells treated with 20 µM TriplatinNC for 24 and 48 hr. Plates are
representative of 4 independent experiments with 2 replicates per sample; mean ± S.D.
of the combined data is shown in Fig. 4-9
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Figure 4-9. Clonogenic Survival Assay. Comparison of colonies formed in
HCT116 p53+/+ cells (black) and HCT116 p53-/- cells (gray) treated with 20
µM TriplatinNC. Percent Inhibition is calculated as: 1-(N/N0), where N=treated
samples and N0= untreated control samples. Data are shown as mean ± S.D.
representative of 4 independent experiments.
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After 48 hr, TriplatinNC induces a robust apoptotic signaling cascade. TriplatinNC induces
apoptosis in mast cells through activation of the mitochondrial-dependent pathway initiator,
procaspase-9, and the downstream effector, procaspase-3 (34). In extension of these studies, it
was determined whether TriplatinNC induced accumulation of the activated forms of
procaspase-9 and procaspase-3 in p53+/+ as compared to p53-/- HCT116 isogenic colon
carcinoma cell lines. Both cells lines show a time-dependent increase in active caspase-9 and
caspase-3 after treatment with 20 µM TriplatinNC (Fig. 4-10A). At 30 or 55 hr after treatment in
p53-/- cells, there is less accumulation of active caspase-9 compared to the untreated control than
in p53+/+ cells. However, the abundance of active caspase-3 appears to be unaffected by the
absence of p53. Therefore, it was asked whether caspase-3 may be activated also by the initiator
of the mitochondrial-independent pathway of apoptosis, caspase-8.

Caspase-8, has the ability to activate procaspase-3 through both mitochondrial-dependent and independent apoptotic pathways. In the mitochondria-dependent pathway, caspase-8 cleaves BID
to tBID, which translocates to the mitochondria and causes damage by culminating an efflux of
death promoting proteins such as cytochrome-C. These events, in turn, lead to activation of
procaspase-9, followed by procaspase-3. In the mitochondrial-independent pathway, caspase-8
instead directly activates procaspase-3, which cleaves downstream substrates such as PARP-1,
eventually leading to cell death (35). In HCT116 cells treated with 20 µM cisplatin for 48 hr, it
was determined that the abundance of active caspase-8 (p18) and downstream target, Parp-1, is
reduced in cells lacking p53 as compared to the wild-type control (Fig. 4-10B). However,
treatment with 20 µM TriplatinNC for 48 hr induced similar levels of active caspase-8 and
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PARP-1 in p53+/+ and p53-/- cells (Fig. 4-10C). Furthermore, TriplatinNC does not induce the
cleavage of BID into tBID (Fig 4-11), therefore, the mitochondrial-dependent and independent
pathways are likely activated independent of each other (36).
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Figure 4-10. TriplatinNC induces activation of caspases independent of p53.
(A) Western Blot Analysis; Time course analysis of cleaved caspase-9 and -3
protein in HCT116 p53+/+ and p53-/- cells treated with 20 µM TriplatinNC for 5,
15, 30, and 55 hr. (B, C) Comparison of cleaved caspase-8 and PARP-1 protein in
HCT116 p53+/+ and p53-/- cells treated with 20 µM Cisplatin or TriplatinNC at 48
hr. β-Actin was used as a loading control.
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Figure 4-11. HCT116 p53+/+ cells were treated with 20 µM Cisplatin or TriplatinNC for
48 hr and comparison of BID (p22) and the active form tBID (p15) proteins were carried
out using immunoblotting . β-Actin was used as a loading control.
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Appendix:

*Synthesis of Cisplatin-2-NBD and TriplatinNC-NBD

N-(7-nitro-2, 1, 3-benzoxadiazol-4-yl)hexane-1,6-diamine
Ligand was synthesized by a modification of a described procedure (A). BOC–diaminohexane
hydrochloride was dissolved in ddH20 and NBD-Cl (5eq) and DIPEA (2eq) was added. After the
mixture had been stirred at room temperature overnight the product was extracted with diethyl
ether. The organic phase was washed with brine (4x10 mL), dried over Na2SO4 and purified by
flash chromatography (CHCl3/EtOAc, 90:10). The BOC protecting group of the purified
intermediate was removed by using trifluoroacetic acid (1 mL) at room temperature. After the
mixture had been stirred overnight, excess TFA was evaporated, and the oily product was treated
with diethyl ether to yield the product as orange crystals.

N-(7-nitro-2,1,3-benzoxadiazol-4-yl)ethane-1,2-diamine(L)
BOC–diaminoethane (0.79 ml, 4.99 mmol) was dissolved in 20 ml ethanol containing a 10%
w/w of Na2CO3, and NBD-Cl (0.50 g, 2.51 mmol) was added. The mixture was stirred at room
temperature overnight, then 50 ml of water were added and the product was extracted with
diethyl ether (3 x 30 ml). The organic phase was washed with brine (3 x 30 ml), dried over
Na2SO4 and purified by flash chromatography (CHCl3/EtOAc, 70:30). The BOC protecting
group of the purified intermediate was removed by using 2 ml of trifluoroacetic acid at room
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temperature. After the mixture had been stirred overnight, excess TFA was evaporated, and the
oily product was treated with diethyl ether to yield the trifluoroacetate salt as orange crystals.

Both ligands were neutralized by dissolving in a mixture of H2O/Ethanol 1:1 and addition of 1
equivalent of NaOH. The neutral ligand was then extracted with CH2Cl2. The organic fractions
were dried over K2CO3 and the solvent removed under vacuum. The product was dried under
vacuum overnight. TriplatinNC-NBD2: BBR3464 Cl- salt was treated with 5.97eq of AgNO3 in
ddH20 and allowed to stir at room temperature for 4 hr. AgCl was filtered off and to the clear
solution was added NBD-diaminohexane (5eq) and DIPEA (5eq). The solution was allowed to
stir at 50oC overnight. The solution was then evaporated to dryness and the resulting orange oil
was re-dissolved in ddH20 and excess NBD-diaminohexane was removed by extraction with
EtOAc (5x50 mL). The aqueous layer was removed and the product was redissolved in ddH20
and lyophilized. The resulting orange powder was washed with EtOAc, CHCl3 and diethyl ether
to yield TriplatinNC-NBD2 (1.7mg, 30%). 1H NMR D2O δ (ppm): 8.54 (d, 2H); 6.23 (d, 2H);
3.00 (t, 12H); 2.72 (m, 4H); 1.67 (m, 16H); 1.42 (m, 16H).

Cis-[PtCl2((N-NBD)ethane-1,2-diamine)(NH3)]
The synthesis of this compound was achieved by means of a modification of a patented
procedure (B). K[PtCl3(NH3)] (30.0 mg, 0.084 mmol) was dissolved in 5 ml of a 15 mM aqueous
solution of KCl. A solution of KI (41 mg, 0.248 mmol) in 1 ml of water was prepared. The KI
solution was added to the K[PtCl3(NH3)] solution, followed by a slight excess of the NBD amino
ligand L (20.5 mg, 0.091 mmol). The combined solution was stirred in the dark for 5 hr at room
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temperature. A reddish precipitate formed which was collected, washed with cold water, cold
methanol, and dried under vacuum at room temperature overnight. The product was Cis-[PtI2((NNBD)ethane-1,2-diamine)(NH3)], confirmed by NMR. The Cis-[PtI2((NNBD)ethane-1,2diamine)(NH3)] (40 mg, 0.067 mmol) was suspended in 2 ml of a mixture H2O/Acetone 85:15
and 1eq of silver nitrate was added to the suspension. It was then stirred for 24 hr in the dark at
room temperature. The suspension was filtered and 200 µL of HCl (~12 M) were added to the
filtrate. The solution was stirred at room temperature for 2 hr, during which time a black
precipitate formed. The precipitate was filtered and the solution concentrated to obtain the
product as a brownish powder, which was washed with ice cold methanol, ether and dried under
vacuum. 1H NMR D2O δ (ppm): 8.45(d, 1H); 6.33 (d, 1H); 3.81 (t, 2H); 3.27 (t, 2H). ESI-MS:
m/z: (M+H)+507.22; (M-Cl)+471.23

(A) Schmidinger, H., Birner-Gruenberger, R.B., Risenhuber, G., Saf, R., Susani-Etzerodt, H.,
Hermetter, A., ChemBioChem 2005, 6, 1776-1781
(B) Wong, E.S.Y., Giandomenico, C.M., Patent No.09678595

*Compounds were synthesized by Brad Benedetti
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CHAPTER 5
FUTURE PERSPECTIVES

Platinum-based compounds that are clinically active and those currently undergoing clinical
trials exhibit conventional mechanisms of inducing cytotoxicity and subsequent downstream
processes. These include activation of multiple cell cycle checkpoints leading to growth arrest
and further activation of cell death mechanisms. The primary mode of cell death exhibited by
these compounds is through the extrinsic or intrinsic pathways of apoptosis which is mediated by
the activation of cysteine aspartate proteases called caspases. However, published results indicate
the role of a second form of cell death or autophagy following treatment with these platinum
compounds. The role of autophagy in cancer progression has been controversial since depending
upon the cellular conditions it either promotes carcinogenesis or prevents cell proliferation. For
instance, earlier reports have shown that inhibition of autophagy prevents senescence which is
believed to be an anti-tumorigenic mechanism1. Another example is seen in the case of
metformin treatment that prevents tumorigenesis through AMPK activation and mTOR
signaling2. In contrast, it has been shown that cancer cells expressing an oncogenic Ras gene can
upregulate autophagy in response to stress and starvation, providing a pro-survival advantage3. It
is postulated that tumor cells depend on autophagic induction to meet the metabolic demands
arising through cellular proliferation and different forms of environmental and therapeutic
stress4. From the perspective of platinum based compounds, it has been shown recently that the
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clinically active oxaliplatin induces a cytoprotective autophagic response in colorectal cancer
cells through the production of reactive oxygen species and induction of endoplasmic reticulum
stress. Inhibiting autophagy by pharmacological intervention using 3-methyladenine or
bafilomycin increased the cytotoxic properties of oxaliplatin in these cells5. A similar activity
was seen in hepatocellular carcinoma cells and xenografts treated with oxaliplatin wherein
cytotoxicity was potentiated using pharmacological inhibition of autophagy6. However, a recent
modification of oxaliplatin called E Platinum has been shown to exhibit anti-tumor properties in
gastric carcinoma BGC-823 cells through the activation of autophagy, suppressing mTOR
activation and other pro-survival signaling pathways7. It is quite interesting to see that structural
modifications in a compound yield a derivative that behaves differently from its parental
compound. Although there are no significant studies done to see whether polynuclear platinum
complexes induce autophagy, it has been shown that the dinuclear platinum compound,
BBR3610 activates an early autophagic and a late apoptotic response in glioma cells8, although
the autophagy induced was found to be neither cytotoxic or cytoprotective. BBR3610-DACH is a
derivative of BBR3610 and both these compounds seem to be activating a non-classical
mechanism of apoptosis in colorectal carcinoma cells as seen from our data wherein PARP
cleavage is observed (more robust after BBR3610-DACH treatment) in the absence of caspase-3
or caspase-7 activation. In this context, some of the experiments that can be carried out in
colorectal carcinoma as well as glioma cells would be to check whether BBR3610-DACH
mimics its parental compound in activating an autophagic response. Also, it would be interesting
to see whether autophagy induction has any role to play in PARP cleavage and whether
pharmacological inhibition of autophagy or genetic knockdown of autophagy related genes
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prevents PARP cleavage or could possibly lead to the induction of a more robust apoptotic
response accompanied with concomitant caspase activation.

As mentioned earlier, the activity of platinum drugs is attributed to the formation of different
kinds of DNA adducts that interfere with normal DNA processes. One of the major hurdles
encountered by DNA binding agents is the chromatin into which the DNA is packaged. The
basic building block on chromatin is the nucleosome which comprises two each of the histone
proteins H2A, H2B, H3, and H4 wrapped around ~146 bp of DNA. Adjacent nucleosomes on the
chromosome are joined by ~20-50 bp of linker DNA9. As such, a major proportion of the
genomic sequence is comprised of histone octamers10. However, not much is known about the
role of DNA binding agents in modulating the nucleosome dynamics. An earlier in vitro study
showed selective disruption of nucleosomes by minor groove binding agents like DAPI which
bind to the AT rich region in the nucleosomes and disrupt the nucleosome by preventing histone
binding or by increasing DNA stiffness11. One of the key factors governing nucleosome
dynamics is the extent of nucleosome mobility. Higher nucleosome mobility destabilizes the
chromatin arrangement whereas lesser nucleosome mobility has been found to stabilize the same,
thus decreasing the accessibility of DNA to non-histone components and DNA binding agents12.
The formation of cisplatin or oxaliplatin adducts reduced the mobility of the nucleosomes but at
the same time, allowed to maintain the nucleosome positioning13. Although adducts form
randomly across the genome, the effects of these drugs on nucleosome positioning allow these
adducts to be protected from DNA repair. The apparent role of the polynuclear platinum
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compounds in regulating the nucleosome dynamics has not been studied in detail and it would be
interesting to see the impact of some of these complexes like BBR3464, BBR3610-DACH, or
TriplatinNC on the nucleosome positioning or mobility. Also, earlier studies using atomic force
microscopy have elucidated the extent of DNA condensation by drugs like cisplatin,
oxaliplatin14, or BBR346415 which accounts for much of the DNA modification by these drugs.
Using a similar approach, it would be exciting to study similar effects on DNA by the dinuclear
platinum complexes, BBR3610 and BBR3610-DACH.

The design and development of novel anti-cancer drugs is an ongoing process and it would be
essential to understand the detailed mechanism of action of these agents for further therapeutic
intervention. In addition to the studies outlined above, an important avenue to shift focus would
be to see the effect of these platinum compounds on the mitochondrial DNA. The surprising find
that colorectal cancers have decreased mitochondrial DNA mutagenesis compared to the normal
cells16, begs the question as to whether some of these platinum compounds could cause
mitochondrial DNA damage via the formation of adducts leading to increased mitochondrial
mutagenesis. Overall, there are different cellular aspects that remain to be explored toward the
development of more potent and efficacious cancer therapeutics.
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